<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AES</journal-id>
<journal-id journal-id-type="hwp">spaes</journal-id>
<journal-id journal-id-type="nlm-ta">Aesthet Surg J</journal-id>
<journal-title>Aesthetic Surgery Journal</journal-title>
<issn pub-type="ppub">1090-820X</issn>
<issn pub-type="epub">1527-330X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1090820X13484492</article-id>
<article-id pub-id-type="publisher-id">10.1177_1090820X13484492</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cosmetic Medicine</subject>
<subj-group subj-group-type="heading">
<subject>Continuing Medical Education Article</subject>
</subj-group>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>10</subject>
<subject>80</subject>
<subject>880</subject>
<subject>881</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Complications of Injectable Fillers, Part I</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>DeLorenzi</surname><given-names>Claudio</given-names></name>
<degrees>MD, FRCS</degrees>
<aff id="aff1-1090820X13484492">Dr DeLorenzi is a plastic surgeon in private practice in Kitchener, Ontario, Canada</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1090820X13484492">Dr Claudio DeLorenzi, 150 Edna Street, Kitchener, ON, N2H 6S1, Canada. E-mail: <email>fillercomplication@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>33</volume>
<issue>4</issue>
<fpage>561</fpage>
<lpage>575</lpage>
<history>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2013 The American Society for Aesthetic Plastic Surgery, Inc.</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">American Society for Aesthetic Plastic Surgery, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Dermal filling has rapidly become one of the most common procedures performed by clinicians worldwide. The vast majority of treatments are successful and patient satisfaction is high. However, complications, both mild and severe, have been reported and result from injection of many different types of dermal fillers. In this Continuing Medical Education review article, the author describes common technical errors, the signs and symptoms of both common and rare complications, and management of sequelae in clear, easily adaptable treatment algorithms.</p>
</abstract>
<kwd-group>
<kwd>filler complication</kwd>
<kwd>hyaluronidase</kwd>
<kwd>dermal filler technique</kwd>
<kwd>filler technique</kwd>
<kwd>biofilms</kwd>
<kwd>filler infection</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Bovine collagen injections were popularized years ago, beginning with Zyderm collagen (Allergan, Inc, Irvine, California) in 1981. Since that time, numerous other products have come to market, the most popular of which are the hyaluronic acid (HA) products (<xref ref-type="table" rid="table1-1090820X13484492">Table 1</xref>). Hyaluronic acid products are linear, unbranched, high molecular weight glycosaminoglycan complex sugars, consisting of alternating d-glucuronic acid and N-acetyl-d-glucosamine. First described by Meyer and Palmer<sup><xref ref-type="bibr" rid="bibr1-1090820X13484492">1</xref></sup> in 1934 during analysis of bovine vitreous, HA is found in the skin and tissues and performs several functions, both physical (eg, lubrication) as well as chemical (as an essential substrate for many different biological processes, including fertility, embryogenesis, morphogenesis, cellular migration, inflammation, and wound healing).<sup><xref ref-type="bibr" rid="bibr2-1090820X13484492">2</xref></sup> In its natural state, HA is an ideal filler material but has an exceptionally short half-life.<sup><xref ref-type="bibr" rid="bibr3-1090820X13484492">3</xref><xref ref-type="bibr" rid="bibr4-1090820X13484492"/><xref ref-type="bibr" rid="bibr5-1090820X13484492"/><xref ref-type="bibr" rid="bibr6-1090820X13484492"/><xref ref-type="bibr" rid="bibr7-1090820X13484492"/><xref ref-type="bibr" rid="bibr8-1090820X13484492"/><xref ref-type="bibr" rid="bibr9-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr10-1090820X13484492">10</xref></sup> Manufacturers have altered the chemistry of HA by crosslinking chains (using various plasticizers such as butanediol diglycidyl ether [BDDE]<sup><xref ref-type="bibr" rid="bibr11-1090820X13484492">11</xref></sup>) to retard natural turnover and increase half-life. By minimally altering the material, manufacturers have been able to create HA products that are well tolerated by the immune system and exhibit favorable properties of longevity and nonreactivity.</p>
<table-wrap id="table1-1090820X13484492" position="float">
<label>Table 1.</label>
<caption>
<p>Dermal Fillers Approved by the FDA Since 1981</p>
</caption>
<graphic alternate-form-of="table1-1090820X13484492" xlink:href="10.1177_1090820X13484492-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="4">Reversible<hr/></th>
</tr>
<tr>
<th/>
<th align="center">Irreversible</th>
<th align="center" colspan="2">Synthetic</th>
<th align="center" colspan="2">Natural Source</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Major component</bold></td>
<td>Polymethylmethacrylate (PMMA)<sup><xref ref-type="table-fn" rid="table-fn2-1090820X13484492">a</xref></sup></td>
<td>Hydroxylapatite<sup><xref ref-type="table-fn" rid="table-fn3-1090820X13484492">b</xref></sup></td>
<td>Poly-L-lactic acid (PLLA)<sup><xref ref-type="table-fn" rid="table-fn4-1090820X13484492">c</xref></sup></td>
<td>Hyaluronic acid<sup><xref ref-type="table-fn" rid="table-fn5-1090820X13484492">d</xref></sup></td>
<td>Collagen<sup><xref ref-type="table-fn" rid="table-fn6-1090820X13484492">e</xref></sup></td>
</tr>
<tr>
<td><bold>Year first approved</bold></td>
<td>2006</td>
<td>2006</td>
<td>2004</td>
<td>2003</td>
<td>1981</td>
</tr>
<tr>
<td><bold>Brand name (manufacturer)</bold></td>
<td>Artefill (Suneva Medical, San Diego, California)</td>
<td>Radiesse (Merz Aesthetics, San Mateo, California)</td>
<td>Sculptra (Valeant, Bridgewater, New Jersey)</td>
<td>Restylane, Perlane (Q-Med [Uppsala, Sweden]/Valeant [Bridgewater, New Jersey])</td>
<td>Zyderm, Zyplast (Allergan)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Hylaform, Hyalform Plus (Genzyme Biosurgery, Ridgefield, New Jersey)</td>
<td>Cosmoderm, Cosmoplast (Allergan)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Juvéderm30, Juvéderm30HV, Juvéderm24HV (Allergan, Irvine, California)</td>
<td>Evolence (ColBar Life Science, Mattawan, Michigan)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>Elevess (Anika Therapeutics, Bedford, Massachusetts)</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1090820X13484492">
<p>This table is not a complete listing of all products available. FDA, US Food and Drug Administration.</p>
</fn>
<fn id="table-fn2-1090820X13484492">
<label>a</label>
<p>Poly(methyl methacrylate) (PMMA): a synthetic nonbiodegradable polymer also used in bone cement and synthetic intraocular lenses. It is formulated in 40-micron microspheres suspended in bovine collagen.</p>
</fn>
<fn id="table-fn3-1090820X13484492">
<label>b</label>
<p>Calcium hydroxylapatite: mineral typically found in teeth and bone. Reconstituted as a gel suspension and injected. Lasts approximately 18 months.</p>
</fn>
<fn id="table-fn4-1090820X13484492">
<label>c</label>
<p>Poly-L-lactic acid: a slowly biodegradable polymer that has been used in suture materials for many years. Results may last up to 2 years, depending on site of injection.</p>
</fn>
<fn id="table-fn5-1090820X13484492">
<label>d</label>
<p>Hyaluronic acid: polysaccharide that binds water and is sourced from avian (eg, rooster combs) or streptococcal bacteria. The polysaccharide is crosslinked to resist degradation, extending its durability from 6 to 18 months, depending on formulation and region injected.</p>
</fn>
<fn id="table-fn6-1090820X13484492">
<label>e</label>
<p>Collagen: protein derived from cow (bovine) or human cells, lasting 3 to 4 months, the shortest duration of any of the dermal fillers. Collagen products have been discontinued and are no longer available.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Early HA manufacturing attempts used animal-sourced raw materials and were plagued by protein contamination issues.<sup><xref ref-type="bibr" rid="bibr12-1090820X13484492">12</xref></sup> As a result, commercial sources of hyaluronates were developed from Lancefield group A and C <italic>Streptococcus equi zooepidemicus</italic>, which naturally produce a pure hyaluronate mucoid capsule. Large quantities of relatively pure hyaluronates could thus be manufactured from bacterial broths that only required purification of relatively primitive bacterial protein contaminants, rather than the complex proteins that contaminated mammalian or avian sources. Attempts to prolong HA longevity in tissues by creating products with more crosslinks between chains resulted in a net decrease in tissue tolerance because of an increase in immune-mediated adverse events (AE). Thus, a balance was necessary whereby natural HA chemical structure was altered enough from its natural state to reduce its susceptibility to breakdown but was not so deviant as to be recognized by the immune system as foreign material.</p>
<p>Although HA remains the dominant filler product for volumizing tissues, other materials are available as well.<sup><xref ref-type="bibr" rid="bibr10-1090820X13484492">10</xref></sup> Permanent dermal fillers include silicone oils, polymethyl methacrylate (PMMA) microspheres, polyacrylamide, and several other materials either alone or formulated in various combinations with resorbable components.<sup><xref ref-type="bibr" rid="bibr13-1090820X13484492">13</xref><xref ref-type="bibr" rid="bibr14-1090820X13484492"/><xref ref-type="bibr" rid="bibr15-1090820X13484492"/><xref ref-type="bibr" rid="bibr16-1090820X13484492"/><xref ref-type="bibr" rid="bibr17-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr18-1090820X13484492">18</xref></sup> The specific complications that may arise from each filler subtype will be ignored for the purposes of this article, and general types of complications will be discussed instead (<xref ref-type="table" rid="table2-1090820X13484492">Table 2</xref>). In terms of a generic classification of dermal fillers, it is helpful to separate them into 2 main classes: reversible and irreversible<sup><xref ref-type="bibr" rid="bibr19-1090820X13484492">19</xref></sup> (rather than temporary vs permanent). Hyaluronic acid fillers are examples of reversible dermal fillers because they may be completely removed with the use of hyaluronidase.<sup><xref ref-type="bibr" rid="bibr19-1090820X13484492">19</xref><xref ref-type="bibr" rid="bibr20-1090820X13484492"/><xref ref-type="bibr" rid="bibr21-1090820X13484492"/><xref ref-type="bibr" rid="bibr22-1090820X13484492"/><xref ref-type="bibr" rid="bibr23-1090820X13484492"/><xref ref-type="bibr" rid="bibr24-1090820X13484492"/><xref ref-type="bibr" rid="bibr25-1090820X13484492"/><xref ref-type="bibr" rid="bibr26-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr27-1090820X13484492">27</xref></sup> Because of the overwhelming popularity of HA fillers, the bulk of this Continuing Medical Education review article will address HA filler complications and summarize clinical case reports, both in the medical literature and those seen by the author in cooperation with manufacturers, other clinicians, and by referral.</p>
<table-wrap id="table2-1090820X13484492" position="float">
<label>Table 2.</label>
<caption>
<p>Filler Complication Classifications</p>
</caption>
<graphic alternate-form-of="table2-1090820X13484492" xlink:href="10.1177_1090820X13484492-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Type</th>
<th align="center">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Technical errors</bold></td>
<td>a. Volume (too much or too little)</td>
</tr>
<tr>
<td/>
<td>b. Depth (too superficial or too deep)</td>
</tr>
<tr>
<td/>
<td>c. Location (wrong location)</td>
</tr>
<tr>
<td/>
<td>d. Product choice (inappropriate product)</td>
</tr>
<tr>
<td><bold>Inflammatory</bold></td>
<td>a. Infectious agent (bacterial, fungal, viral, or biofilm mediated)</td>
</tr>
<tr>
<td/>
<td>b. Immune mediated (not related to infectious agent)</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section1-1090820X13484492">
<title>Technical Aesthetic Complications</title>
<p>As with any complication in medicine, avoidance is far preferable to management. Fillers are classified by the US Food and Drug Administration (FDA) as devices, not medications. Therefore, the same precautions taken with other implantable devices apply with dermal fillers. However, the occurrence of posttreatment complications in some patients is inevitable. Reversible HA fillers have the very beneficial quality of responding to hyaluronidase, which allows the physician to simply remove all injected material and start over at a later time. The following complications can be addressed relatively easily if they result from reversible fillers:</p>
<list id="list1-1090820X13484492" list-type="order">
<list-item><p>Volume: too much or too little filler</p></list-item>
<list-item><p>Depth of treatment: filler injected too superficially or too deep</p></list-item>
<list-item><p>Location: unfavorable anatomic location or asymmetry, or injection into the incorrect anatomical location</p></list-item>
</list>
<p>Problems with irreversible fillers are much more difficult to manage, especially if vital structures have been treated. Excision of filler product<sup><xref ref-type="bibr" rid="bibr28-1090820X13484492">28</xref><xref ref-type="bibr" rid="bibr29-1090820X13484492"/><xref ref-type="bibr" rid="bibr30-1090820X13484492"/><xref ref-type="bibr" rid="bibr31-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr32-1090820X13484492">32</xref></sup> may be possible in some areas without causing too much damage to vital structures and minor errors of symmetry or insufficient volume may be addressed by adding more product, but irreversible fillers cannot easily be removed. Therefore, the author strongly recommends that they not be considered as a first-line choice and should be used only by clinicians with substantial training and experience with these filler agents. Even in the best hands, complications may occur, and this calls for extreme caution, especially when injecting the product around vital facial structures.</p>
<p>Dermal fillers of chemically different families generally should not be injected into the same anatomic location because it may obfuscate any attempt to correlate an adverse reaction with its causative filler. Although literature support for this hypothesis is scant,<sup><xref ref-type="bibr" rid="bibr33-1090820X13484492">33</xref></sup> the author’s clinical experience suggests that HA fillers injected over irreversible fillers (eg, PMMA) may exacerbate/stimulate nodule formation. This may be related to the biofilm hypothesis,<sup><xref ref-type="bibr" rid="bibr34-1090820X13484492">34</xref><xref ref-type="bibr" rid="bibr35-1090820X13484492"/><xref ref-type="bibr" rid="bibr36-1090820X13484492"/><xref ref-type="bibr" rid="bibr37-1090820X13484492"/><xref ref-type="bibr" rid="bibr38-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr39-1090820X13484492">39</xref></sup> which will be discussed later, or to some as yet unknown process. A patient registry failed to illustrate an increased risk of nodules from filler mixing, but the sample size was small and the data set regarding the fillers administered was incomplete.<sup><xref ref-type="bibr" rid="bibr40-1090820X13484492">40</xref></sup></p>
<p>Factors that may play an important role in the development of foreign body reactions include particle size and degree of smoothness,<sup><xref ref-type="bibr" rid="bibr41-1090820X13484492">41</xref></sup> chemical composition, surface charge,<sup><xref ref-type="bibr" rid="bibr42-1090820X13484492">42</xref></sup> particle concentration, immunogenicity, and hydrophilicity.<sup><xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref></sup> When we add to these the multiplicity of chemical and physical interactions possible between materials of differing chemical composition that may occur when these materials are simultaneously injected into the same area, we make the task of trying to isolate causal factors ever more difficult. The author believes that some patients with whom he has consulted regarding this phenomenon experienced complications related to the introduction of small numbers of bacteria (particularly atypical organisms, such as mycobacteria) into an area with an existing dermal implant (foreign body), which is consistent with the biofilm hypothesis. Before describing the most commonly seen categories of dermal filler complications and suggesting strategies for management that have been useful in clinical practice, it may be helpful to review the properties of hyaluronidase.</p>
<sec id="section2-1090820X13484492">
<title>Hyaluronidase</title>
<p>Hyaluronidase (HYAL) is a mucolytic enzyme that hydrolyzes both natural and crosslinked HA dermal fillers. Just as HA appears in so many areas of the human body, HYAL is also thought to play important roles in many natural biochemical processes<sup><xref ref-type="bibr" rid="bibr43-1090820X13484492">43</xref></sup> and has proven useful in clinical medicine. It has been applied, for example, in the dispersion of local anesthetics,<sup><xref ref-type="bibr" rid="bibr44-1090820X13484492">44</xref></sup> administration of resuscitation fluids by hypodermoclysis,<sup><xref ref-type="bibr" rid="bibr45-1090820X13484492">45</xref></sup> and fertility studies.<sup><xref ref-type="bibr" rid="bibr46-1090820X13484492">46</xref><xref ref-type="bibr" rid="bibr47-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr48-1090820X13484492">48</xref></sup> Hyaluronidase was initially isolated from microorganisms and subsequently from bovine testis and most recently by recombinant technology. The biology of HA metabolism is far from being completely understood in animal models, let alone in humans.<sup><xref ref-type="bibr" rid="bibr49-1090820X13484492">49</xref></sup> Furthermore, HYAL is not a single moiety; rather, it represents a family of compounds with similar but not identical effects in mammals.<sup><xref ref-type="bibr" rid="bibr2-1090820X13484492">2</xref>,<xref ref-type="bibr" rid="bibr50-1090820X13484492">50</xref></sup> There are 3 distinct groups of HYAL: (1) mammalian, (2) bacterial, and (3) from leeches, crustaceans, and some parasites.<sup><xref ref-type="bibr" rid="bibr2-1090820X13484492">2</xref></sup> Different formulations of HYAL are available for clinical use in different countries, which makes it difficult to describe the correct use of these various products, since activity level varies by type, pH, and a host of other biochemical factors. In some countries, there are no commercial, “pharmaceutical grade” sources of HYAL available. Clinicians in these countries obtain HYAL from compounding pharmacies, from which product variation in purity, stability, and effectiveness creates even more problems for the clinician. Comments in the literature about the dosage, dilution, and subsequent effectiveness of HYAL must be tempered by the understanding that the source of the product is likely unknown, unless it is specified in the article.</p>
<p>Hyaluronidase of the mammalian type generally splits naturally occurring HA into smaller oligomers (mainly hexasaccharides).<sup><xref ref-type="bibr" rid="bibr2-1090820X13484492">2</xref></sup> However, the biochemical interaction between HYAL and commercially sold, crosslinked HA may be altogether different. The amounts, dilution, and method of administration can thus only be discussed with respect to the specific agent being injected. The literature offers several examples of widely divergent doses, but the author recommends that the actual quantity administered be titrated to effect—that is, to use as much as necessary to achieve the desired clinical results. If there is no history of patient allergy to HYAL or to any of the ingredients, the author uses a starting dose of 150 IU but has also injected up to 1500 IU in cases of vascular compromise. It is important to keep in mind the distinction between animal-sourced and recombinant human HYAL since the associated animal protein in the former may be a source of grief and consternation (causing unintentional immune mediated reactions in some patients).</p>
<p>Hyaluronidase may be diluted with local anesthetics or normal saline, but it is crucial to be watchful of the pH of various diluents since it may adversely affect the efficiency of HYAL. It may be injected directly and slowly into the affected site to initiate hydrolysis of the previously injected HA. Injecting a small amount of suitable local anesthesia will facilitate massage, which is very important in obtaining the therapeutic effect. The nature and quality of the dermal HA filler product are an important consideration for the effectiveness of HYAL. For example, if a particulate form of dermal filler is used (eg, Restylane; Q-Med, Uppsala, Sweden; distributed in North America by Medicis Aesthetics, Scottsdale, Arizona), HYAL can quickly surround the granules of heavily crosslinked HA and hydrolize the material over a broad surface area, several orders of magnitude larger than that of monophasic products (eg, Juvéderm; Allergan, Inc). The latter takes significantly longer to clinically disperse than the former, presumably because of this fundamental biochemical difference. The Restylane family of products is generally produced by creating a crosslinked matrix, which is subsequently separated into particles that are then suspended and lubricated by minimally or completely non-crosslinked HA. The non-crosslinked HA fraction responds immediately (in seconds to minutes) to HYAL, allowing it to surround the small particles. With the Juvéderm family of products, HYAL can only affect the outermost surface of the aliquot, taking far longer to break down the HA. In the author’s experience, massage is essential to mechanically mix the HYAL with the HA and promote hydrolysis in the clinical setting. The author tested these principles in vitro in unpublished work and found that the same phenomenon was easily demonstrable; granular product liquefied very quickly, whereas monophasic product took far longer. Readers are encouraged to verify the veracity of this phenomenon with their own HA filler products, since it is both instructive and has direct clinical application.</p>
<p>Formerly, most HYAL preparations were animal-sourced products, and the literature offers several examples of allergic phenomena occurring in patients treated with retrobulbar blocks associated with ophthalmic surgery.<sup><xref ref-type="bibr" rid="bibr51-1090820X13484492">51</xref><xref ref-type="bibr" rid="bibr52-1090820X13484492"/><xref ref-type="bibr" rid="bibr53-1090820X13484492"/><xref ref-type="bibr" rid="bibr54-1090820X13484492"/><xref ref-type="bibr" rid="bibr55-1090820X13484492"/><xref ref-type="bibr" rid="bibr56-1090820X13484492"/><xref ref-type="bibr" rid="bibr57-1090820X13484492"/><xref ref-type="bibr" rid="bibr58-1090820X13484492"/><xref ref-type="bibr" rid="bibr59-1090820X13484492"/><xref ref-type="bibr" rid="bibr60-1090820X13484492"/><xref ref-type="bibr" rid="bibr61-1090820X13484492"/><xref ref-type="bibr" rid="bibr62-1090820X13484492"/><xref ref-type="bibr" rid="bibr63-1090820X13484492"/><xref ref-type="bibr" rid="bibr64-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr65-1090820X13484492">65</xref></sup> Anaphylaxis has been described following HYAL administration,<sup><xref ref-type="bibr" rid="bibr62-1090820X13484492">62</xref>,<xref ref-type="bibr" rid="bibr66-1090820X13484492">66</xref><xref ref-type="bibr" rid="bibr67-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr68-1090820X13484492">68</xref></sup> although this appears to be rare and was likely due to bovine serum proteins in the preparations<sup><xref ref-type="bibr" rid="bibr65-1090820X13484492">65</xref></sup>; reaction may occur even in patients with no known previous exposure. The venom of stinging insects may contain HYAL, and this mechanism may be the source of sensitization in affected individuals.</p>
<p>Hyaluronidase has proven very helpful in the management of many of the complications that may arise from the injection of HA-based dermal fillers.<xref ref-type="fn" rid="fn1-1090820X13484492">*</xref> Clinicians are encouraged to have it readily available to treat asymmetry or unfavorable cosmetic outcomes after HA injection, especially in urgent or emergency situations such as impending necrosis due to vascular compromise.</p>
<sec id="section3-1090820X13484492">
<title>Retroseptal or Premalar Filler Injection</title>
<p>As filling of the infraorbital region (nasojugal area) has become more popular,<sup><xref ref-type="bibr" rid="bibr69-1090820X13484492">69</xref>,<xref ref-type="bibr" rid="bibr81-1090820X13484492">81</xref>,<xref ref-type="bibr" rid="bibr82-1090820X13484492">82</xref></sup> there has been an increase in accidental retroseptal injection (<xref ref-type="fig" rid="fig1-1090820X13484492">Figure 1</xref>). A similar phenomenon may occur with injections anterior to the orbitomalar septum, as described by Pessa et al,<sup><xref ref-type="bibr" rid="bibr83-1090820X13484492">83</xref>,<xref ref-type="bibr" rid="bibr84-1090820X13484492">84</xref></sup> resulting in troubling, persistent premalar edema. The orbital septum may accidentally be penetrated when injecting into the infraorbital area, where filler product may be injected behind the orbital septum or anterior to the orbitomalar septum.<sup><xref ref-type="bibr" rid="bibr85-1090820X13484492">85</xref></sup> This may occur when the injector treats too high, treats too close to the infraorbital rim, injects too deep, accidentally penetrates the septum, or simply injects too much product when the integrity of the septum has been previously breached (as with a popular fat repositioning type of blepharoplasty). This results in the appearance of sometimes dramatic eyelid bags where none existed prior to filler treatment. A similar phenomenon occurs with superficial injections of material anterior to the malar septum, which results in severe premalar edema.</p>
<fig id="fig1-1090820X13484492" position="float">
<label>Figure 1.</label>
<caption>
<p>(A) Typical appearance following accidental retroseptal injection of hyaluronic acid (HA)–based filler product, which may occur when treating the nasojugal area if injection accidentally penetrates the orbital septum. The HA material causes persistent nonpitting edema of the inferior periorbital area. (B) Typical appearance immediately following initial treatment with hyaluronidase and gentle massage for correction of retroseptal injection. Note the rapid resolution of edema of the inferior orbital area (above the orbital rim). (C) Typical appearance approximately 1 week posttreatment.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig1.tif"/>
</fig>
<p>After making the diagnosis, treatment of these improper injections consists of careful injection of HYAL into the area<sup><xref ref-type="bibr" rid="bibr69-1090820X13484492">69</xref></sup> and subsequent massage to diffuse the HYAL and bring it into contact with the injected filler. A thorough understanding of the anatomy of each region treated with HA is important and is especially crucial with these injections, as the septum may dip below the bony infraorbital margin.<sup><xref ref-type="bibr" rid="bibr86-1090820X13484492">86</xref><xref ref-type="bibr" rid="bibr87-1090820X13484492"/><xref ref-type="bibr" rid="bibr88-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr89-1090820X13484492">89</xref></sup> Hyaluronic acid binds to water,<sup><xref ref-type="bibr" rid="bibr90-1090820X13484492">90</xref>,<xref ref-type="bibr" rid="bibr91-1090820X13484492">91</xref></sup> which may result in significant edema in the retroseptal soft tissues with only a tiny amount of misplaced filler. Good technique involves treating deep to the orbicularis muscle and orbitomalar septum and carefully approaching this area from below to avoid retroseptal injection<sup><xref ref-type="bibr" rid="bibr69-1090820X13484492">69</xref>,<xref ref-type="bibr" rid="bibr81-1090820X13484492">81</xref></sup> or injection anterior to the orbitomalar septum,<sup><xref ref-type="bibr" rid="bibr85-1090820X13484492">85</xref></sup> which may cause premalar edema.</p>
<p>The author has conferred with several patients who experienced these complications after HA treatment and underwent months of ineffective treatment with cardiac drugs, powerful diuretics, compression, steroids, and other interventions. A small dosage of HYAL can sometimes result in dramatic and immediate improvement. Those who have been injected with calcium hydroxylapatite (Radiesse; Merz Aesthetics, San Mateo, California) may be treated with injections of sterile water or saline (with or without lidocaine for local anesthesia) along with massage to help to mechanically dilute the material. Permanent fillers are far more difficult to treat in the presence of these complications, and excision may be the only possible remedy in some cases. However, HYAL treatment may produce positive results and involves a gentle injection of 25 to 100 IU into the affected areas followed by gentle massage. Because of the great variability in the various formulations of HYAL available in different regions, many of which are compounded by local pharmacies, it is best to treat to effect, rather than by absolute dosage. In other words, physicians should inject as much HYAL as required to achieve the desired effect. Although both naturally occurring, resident HA as well as artificial HA are affected by HYAL, the former is more sensitive than the latter because artificial HA is always crosslinked to various degrees. It is also important to remember that particulate forms of HA derivatives (such as the Restylane family of products) respond at a faster rate than the monophasic types (such as Juvéderm).</p>
</sec>
<sec id="section4-1090820X13484492">
<title>Tyndall Effect</title>
<p>The Tyndall effect (<xref ref-type="fig" rid="fig2-1090820X13484492">Figure 2</xref>) results from injection of HA fillers too close to the surface of the skin, which yields a “bluish” discoloration that may be readily treated with HYAL.<sup><xref ref-type="bibr" rid="bibr23-1090820X13484492">23</xref>,<xref ref-type="bibr" rid="bibr92-1090820X13484492">92</xref><xref ref-type="bibr" rid="bibr93-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr94-1090820X13484492">94</xref></sup> The HA filler causes discoloration due to the refraction of light, so that melanin deep in the dermis displays a blue tint, resulting in “Mongolian spots.” The Tyndall effect looks somewhat like a mild but deep bruise (with which it may often be confused); it does not change over time until the material is removed.</p>
<fig id="fig2-1090820X13484492" position="float">
<label>Figure 2.</label>
<caption>
<p>(A) Typical appearance of the Tyndall effect following hyaluronic acid injection. The “bluish” discoloration may be confused with persistent bruising in the periorbital tissues; it is also frequently seen in the nasolabial fold region. (B) Typical appearance immediately following treatment with hyaluronidase. (C) Typical appearance approximately 1 week posttreatment.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig2.tif"/>
</fig>
<p>Treatment of the Tyndall effect consists of HYAL injection into the surrounding tissues and subsequent gentle massage.<sup><xref ref-type="bibr" rid="bibr23-1090820X13484492">23</xref>,<xref ref-type="bibr" rid="bibr92-1090820X13484492">92</xref>,<xref ref-type="bibr" rid="bibr94-1090820X13484492">94</xref></sup> The amount of HYAL that should be injected is not standardized, but the author’s personal experience suggests that 15 to 50 IU produces a good result. Clinical judgment should be exercised while dosage is titrated to effect, again based on varying HYAL formulations. Massage of the material is essential to increase the effect of the enzyme. Only modest pressure is required, and simply rolling a cotton-tipped swab over the tissues is sufficient to disperse HYAL over the area.</p>
</sec>
</sec>
<sec id="section5-1090820X13484492">
<title>Lumps and Nodules</title>
<p>Lumps and nodules can be caused by almost any filler when too much is injected into a small area, for a variety of reasons (<xref ref-type="fig" rid="fig3-1090820X13484492">Figure 3</xref>).<sup><xref ref-type="bibr" rid="bibr30-1090820X13484492">30</xref><xref ref-type="bibr" rid="bibr31-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr32-1090820X13484492">32</xref>,<xref ref-type="bibr" rid="bibr35-1090820X13484492">35</xref>,<xref ref-type="bibr" rid="bibr37-1090820X13484492">37</xref>,<xref ref-type="bibr" rid="bibr39-1090820X13484492">39</xref>,<xref ref-type="bibr" rid="bibr95-1090820X13484492">95</xref><xref ref-type="bibr" rid="bibr96-1090820X13484492"/><xref ref-type="bibr" rid="bibr97-1090820X13484492"/><xref ref-type="bibr" rid="bibr98-1090820X13484492"/><xref ref-type="bibr" rid="bibr99-1090820X13484492"/><xref ref-type="bibr" rid="bibr100-1090820X13484492"/><xref ref-type="bibr" rid="bibr101-1090820X13484492"/><xref ref-type="bibr" rid="bibr102-1090820X13484492"/><xref ref-type="bibr" rid="bibr103-1090820X13484492"/><xref ref-type="bibr" rid="bibr104-1090820X13484492"/><xref ref-type="bibr" rid="bibr105-1090820X13484492"/><xref ref-type="bibr" rid="bibr106-1090820X13484492"/><xref ref-type="bibr" rid="bibr107-1090820X13484492"/><xref ref-type="bibr" rid="bibr108-1090820X13484492"/><xref ref-type="bibr" rid="bibr109-1090820X13484492"/><xref ref-type="bibr" rid="bibr110-1090820X13484492"/><xref ref-type="bibr" rid="bibr111-1090820X13484492"/><xref ref-type="bibr" rid="bibr112-1090820X13484492"/><xref ref-type="bibr" rid="bibr113-1090820X13484492"/><xref ref-type="bibr" rid="bibr114-1090820X13484492"/><xref ref-type="bibr" rid="bibr115-1090820X13484492"/><xref ref-type="bibr" rid="bibr116-1090820X13484492"/><xref ref-type="bibr" rid="bibr117-1090820X13484492"/><xref ref-type="bibr" rid="bibr118-1090820X13484492"/><xref ref-type="bibr" rid="bibr119-1090820X13484492"/><xref ref-type="bibr" rid="bibr120-1090820X13484492"/><xref ref-type="bibr" rid="bibr121-1090820X13484492"/><xref ref-type="bibr" rid="bibr122-1090820X13484492"/><xref ref-type="bibr" rid="bibr123-1090820X13484492"/><xref ref-type="bibr" rid="bibr124-1090820X13484492"/><xref ref-type="bibr" rid="bibr125-1090820X13484492"/><xref ref-type="bibr" rid="bibr126-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr127-1090820X13484492">127</xref></sup> For example, if the syringe is “sticky” and the injector places too much pressure on the plunger, a sudden release may accidentally dispense more filler than intended. The resulting lump or nodule is usually easily treated with a simple incision and drainage using a sharp disposable needle (<xref ref-type="fig" rid="fig3-1090820X13484492">Figure 3</xref>).</p>
<fig id="fig3-1090820X13484492" position="float">
<label>Figure 3.</label>
<caption>
<p>This 38-year-old woman presented with a submucosal nodule 1 month after hyaluronic acid filler treatment. Puncture (incision and drainage) was performed with a 21-gauge needle.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig3.tif"/>
</fig>
<p>If nodules due to excess product are multiple or deep, a formal incision and drainage may not be feasible. In such cases, HA products can be treated with HYAL. Capsular contracture around tissue fillers is quite rare, but the author has seen and treated these on occasion. If a large amount of filler has been injected into an area with the “lake technique,” the resulting rare complication may present as a nodule or lump that becomes increasingly prominent as contraction of the capsule creates a spherical shape (analogous to a hardening breast implant capsule). The sphere is formed to hold the largest volume relative to the least surface area, which creates the deformity. This capsule may cause the patient pain and discomfort. A small amount of local anesthesia may be needed to pass a larger-bore needle or 16-gauge Luer-Lok syringe to break through the capsule and aspirate the material within. Hyaluronidase may be administered to clean up whatever remains behind. It may also be administered to attempt to treat nodules that are not responding to aspiration, even in patients who were injected with a material of unknown origin. (It should be noted that patients are only rarely aware of the products they received, and some may not even remember the name of the physician who originally injected them.) Hyaluronidase should be used with caution if infection is suspected, since this may result in spreading of the infection to surrounding areas. Nodules caused by other types of dermal fillers have varied etiology, including incorrect dilution or reconstitution, or incorrect placement or technique.<sup><xref ref-type="fn" rid="fn2-1090820X13484492">†</xref></sup> Simple excision may suffice in straightforward cases, but multiple nodules within vital anatomic structures pose great challenges to surgeons, and often call for unique methods of treatment (<xref ref-type="fig" rid="fig4-1090820X13484492">Figure 4</xref>).<sup><xref ref-type="bibr" rid="bibr128-1090820X13484492">128</xref></sup></p>
<fig id="fig4-1090820X13484492" position="float">
<label>Figure 4.</label>
<caption>
<p>This 42-year-old woman received an inappropriate volume of PMMA-based permanent filler and presented to the author with multiple nodules along the vermillion. Biopsy confirmed 40 micron microspheres and no abnormal inflammatory response. Treatment options were limited and patient decided against surgical excision because of risk of scarring.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section6-1090820X13484492">
<title>Inflammatory Complications</title>
<sec id="section7-1090820X13484492">
<title>Infection</title>
<p>Infection following filler treatment is uncommon<sup><xref ref-type="bibr" rid="bibr129-1090820X13484492">129</xref></sup> but may be caused by bacterial, viral, and <italic>Candida</italic> species, and it may sometimes occur as polymicrobial infection. The most common viral infection to occur in the skin after injection is herpes simplex. Patients with a strong history of cold sores or fever blisters may be pretreated with acyclovir, famciclovir, or valacyclovir to reduce the severity and duration of cutaneous herpes infections. If there is any question of ocular infection, consultation with an ophthalmologist is recommended, since surgical debridement of the cornea may be required. The initial presentation of clear vesicles in the skin may not be evident in some cases, and some patients will develop secondary bacterial infections, further confusing clinical analysis.<sup><xref ref-type="bibr" rid="bibr130-1090820X13484492">130</xref>,<xref ref-type="bibr" rid="bibr131-1090820X13484492">131</xref></sup> In cases where the etiology is uncertain and local laboratory support is lacking,<sup><xref ref-type="bibr" rid="bibr132-1090820X13484492">132</xref></sup> a multipronged approach is reasonable, utilizing both antibiotics and antiviral agents. Impetigenized herpes simplex is not uncommon (<xref ref-type="fig" rid="fig5-1090820X13484492">Figure 5</xref>). <italic>Candida</italic> species may sometimes complicate the picture further and should be kept in consideration for immunocompromised patients and those not responding to treatment with antiviral agents and antibiotics alone.<sup><xref ref-type="bibr" rid="bibr133-1090820X13484492">133</xref></sup></p>
<fig id="fig5-1090820X13484492" position="float">
<label>Figure 5.</label>
<caption>
<p>Herpes simplex type 1 may present as small, clear vesicles on the skin of the face a few days after filler treatment. The lesions often become secondarily infected with <italic>Staph aureus</italic> or Group A strep, leading to the relatively common presentation of impetigenized herpes simplex. Treatment typically consists of acyclovir and a cephalosporin as well as routine topical wound care. Note risk of confusion with vascular compromise. The timing of presentation is important, since vascular events begin at the time of injection, and herpetic lesions usually begin a few days after injection.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig5.tif"/>
</fig>
<p>Rarely, patients may present with multiple red, tender lumps along with signs and symptoms of infection. True granulomatous inflammation may also be present in multiple, simultaneous sites of involvement since it is a systemic response (see below). If a single facial abscess occurs, it would be reasonable to assume that contamination through the skin occurred during treatment. However, if a patient presents with multiple abscesses, it is reasonable to assume that contamination occurred in the syringe prior to injection. Unfortunately, mixing or reformulating products in less-than-ideal conditions is a common occurrence in clinics. Dramatic complications due to microbial contamination of the material may result from these unfortunate instances (<xref ref-type="fig" rid="fig6-1090820X13484492">Figure 6</xref>). Abscesses should not be treated with antibiotics alone, although they may be treated with incision and drainage alone in the absence of surrounding cellulitis.</p>
<fig id="fig6-1090820X13484492" position="float">
<label>Figure 6.</label>
<caption>
<p>Subcutaneous abscesses such as those shown in this illustration can occur after injection of reformulated filler. Such abscesses are treated with incision and drainage.</p>
</caption>
<graphic xlink:href="10.1177_1090820X13484492-fig6.tif"/>
</fig>
<p>Hyaluronidase should not be used in the primary phase of treatment, due to the risk of spreading the infected material diffusely into the tissues if active cellulitis is present. Many bacteria (eg, staphylococci, streptococci, and anaerobes) naturally produce HYAL, which plays a role in their pathogenicity and allows them to spread quickly through the subcutaneous tissues, consuming hyaluronan as they go. The infection should first be controlled with incision and drainage, followed by HYAL if necessary. The author recently treated a patient who presented with recurrent ipsilateral cheek abscess formation on 3 separate occasions despite thorough incision, drainage, and courses of culture-appropriate oral antibiotics. Each of these treatments was apparently successful, but the condition continued to recur after a few weeks. After she was treated with HYAL, no further infection recurred.</p>
</sec>
<sec id="section8-1090820X13484492">
<title>Biofilms</title>
<p>Biofilms have been implicated in the development of some filler complications.<sup><xref ref-type="bibr" rid="bibr34-1090820X13484492">34</xref>,<xref ref-type="bibr" rid="bibr36-1090820X13484492">36</xref>,<xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref>,<xref ref-type="bibr" rid="bibr39-1090820X13484492">39</xref>,<xref ref-type="bibr" rid="bibr99-1090820X13484492">99</xref>,<xref ref-type="bibr" rid="bibr134-1090820X13484492">134</xref></sup> Because bacteria can safely hide from immune defenses when ensconced in their biofilm fortress, antibiotics cannot reach them. As a result, when conditions are favorable, the bacteria can emerge from their planktonic state and reestablish active infection.<sup><xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref>,<xref ref-type="bibr" rid="bibr135-1090820X13484492">135</xref>,<xref ref-type="bibr" rid="bibr136-1090820X13484492">136</xref></sup> Some bacteria secrete a self-made extracellular polymeric substance—a highly protective “slime layer”<sup><xref ref-type="bibr" rid="bibr137-1090820X13484492">137</xref></sup>—that acts as a form of armor, blocking out the local environment to the point that antimicrobial drugs are no longer effective.<sup><xref ref-type="bibr" rid="bibr138-1090820X13484492">138</xref>,<xref ref-type="bibr" rid="bibr139-1090820X13484492">139</xref></sup> Any type of implant, including all fillers, significantly reduces the threshold at which contaminating bacteria can cause infection.<sup><xref ref-type="bibr" rid="bibr140-1090820X13484492">140</xref>,<xref ref-type="bibr" rid="bibr141-1090820X13484492">141</xref></sup> Once a biofilm has developed, the bacteria have a “safe room,”<sup><xref ref-type="bibr" rid="bibr142-1090820X13484492">142</xref></sup> and neither the immune system nor drugs or medication can penetrate the protective layer.<sup><xref ref-type="bibr" rid="bibr140-1090820X13484492">140</xref></sup> Thus, bacteria can lie dormant for very long periods, only to reawaken and cause more problems once the environment is favorable again. When they do arise from their planktonic state, they can cause granulomatous inflammation, abscesses, nodules, and even full-blown recurrent infection.<sup><xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref></sup> Until the foreign body is completely removed, it is difficult if not impossible to remove the biofilm; the bacteria are irreversibly bound to the foreign material. Furthermore, inflammation may be reactivated by punctures of repeated injections.<sup><xref ref-type="bibr" rid="bibr143-1090820X13484492">143</xref></sup> With solid implants, such as hip or knee joint prostheses, it is impossible to completely clean the devices ex vivo, and they must be replaced.<sup><xref ref-type="bibr" rid="bibr144-1090820X13484492">144</xref>,<xref ref-type="bibr" rid="bibr145-1090820X13484492">145</xref></sup> New strategies for addressing this issue in solid implants include drug-eluting implant coatings,<sup><xref ref-type="bibr" rid="bibr146-1090820X13484492">146</xref></sup> and future permanent fillers may utilize this strategy. With permanent fillers (eg, PMMA), excision may be the only recourse available. If permanent implants are used in vital structures such as the lips or eyelids, clinical options are limited and difficult choices must be made (<xref ref-type="fig" rid="fig4-1090820X13484492">Figure 4</xref>). The clinician should consider these issues carefully when selecting between permanent or long-lasting fillers in such critical structures. The simplicity of being able to remove HA fillers with HYAL is a very strong benefit.</p>
<p>To date, it has not been conclusively proven that biofilms are involved in granuloma formation, but several recent studies present arguments in favor of this hypothesis.<sup><xref ref-type="fn" rid="fn3-1090820X13484492">‡</xref></sup> One of these has reported detection of bacteria in culture-negative filler lesions.<sup><xref ref-type="bibr" rid="bibr37-1090820X13484492">37</xref></sup> Considering that these fillers are analogous to permanent implants, one wonders at the often lackadaisical manner in which they are commonly demonstrated at clinical teaching symposia, sometimes in unsanitary locations such as hotel rooms and auditoriums. Skin preparation prior to injection should follow standard procedure, which has reduced iatrogenic infection for more than 150 years.<sup><xref ref-type="bibr" rid="bibr150-1090820X13484492">150</xref></sup> Although no evidence-based studies exist on the correct choice for skin preparation prior to dermal filler injection, it seems prudent to follow guidelines for reduction of health care–associated infection.<sup><xref ref-type="bibr" rid="bibr151-1090820X13484492">151</xref><xref ref-type="bibr" rid="bibr152-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr153-1090820X13484492">153</xref></sup> These reports recommend the application of 2% chlorhexidine gluconate in 70% alcohol as skin preparation prior to insertion of venous catheters.<sup><xref ref-type="bibr" rid="bibr154-1090820X13484492">154</xref></sup> Disposable sterile dressing trays with containers for prep solution, gauze, and disposable sterile drapes are convenient and inexpensive, and they provide a safe, clean work area in an office setting. To date, there is no proof that a simple alcohol swab prep and the use of nonsterile gloves is insufficient in preventing granulomas or filler infections, but the author believes that transferring surgical expertise in sterile technique to the clinic treatment room may further reduce the prevalence of these complications.</p>
<p>An important distinction between nodules and granulomas is that the former is descriptive; it is the correct term whenever a pathological diagnosis is not available. The latter term should only be used when pathological specimens have been obtained and the required pathological criteria for granulomas have been satisfied—typically described in pathology textbooks as clumps of plump macrophages with hematoxylin-stained nuclei, multinucleated giant cells, and sometimes peripheral lymphocytes. Too often, clinicians refer to all nodules as “granulomas” when no histological pathology has been performed. This is an error that results in sloppy planning and treatment. A nodule should not be diagnosed as a granuloma until it has been confirmed as such.</p>
</sec>
<sec id="section9-1090820X13484492">
<title>Immune-Mediated (Noninfectious)</title>
<p>When considering the causes of inflammation apart from infection, product sensitivity and immune-mediated inflammation are of particular importance.<sup><xref ref-type="bibr" rid="bibr20-1090820X13484492">20</xref>,<xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref>,<xref ref-type="bibr" rid="bibr101-1090820X13484492">101</xref>,<xref ref-type="bibr" rid="bibr106-1090820X13484492">106</xref>,<xref ref-type="bibr" rid="bibr155-1090820X13484492">155</xref><xref ref-type="bibr" rid="bibr156-1090820X13484492"/><xref ref-type="bibr" rid="bibr157-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr158-1090820X13484492">158</xref></sup> When Restylane was first formulated, its manufacturer was producing a raw substrate procured from a biologics company that turned out to have an unacceptably high impurity rate. As a result, a moderate number of patients had various inflammatory complications following filler treatment. The company subsequently sourced higher-purity raw materials and significantly reformulated its product. This all occurred prior to FDA approval studies conducted in the United States. The literature is replete with similar stories involving other fillers, many of which moved from country to country, changing names each time to counter reports of AE occurring with earlier formulations. For example, Artefill (Suneva Medical, Inc, San Diego, California) went through several name and formulation changes prior to being approved in the United States. Similar stories can be found with many other products that originated in Eastern European and Asian countries. Somehow, these companies were able to create “clean slates” each time, renaming and tweaking their products as they sought new markets for approval.</p>
<p>As mentioned earlier, sometimes patients are unaware of the nature of the product with which they have been injected. Many patients also forget that they received a specific filler. Therefore, it is important, when possible, to obtain a tissue diagnosis of the problem area. Often, these diagnoses surprise both surgeons and patients, some of whom were not told that they had been injected with silicone, PMMA, or other fillers. Unfortunately, some physicians go as far as to falsify their medical records, and patients in search of a “good deal” are sometimes treated by unlicensed practitioners and are injected with illegal substances such as bathtub caulk, as reported in a recently publicized case that resulted in death.<sup><xref ref-type="bibr" rid="bibr159-1090820X13484492">159</xref><xref ref-type="bibr" rid="bibr160-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr161-1090820X13484492">161</xref></sup></p>
<p>A large number of publications report granulomatous inflammation involving almost every kind of filler available.<sup><xref ref-type="fn" rid="fn4-1090820X13484492">§</xref></sup> There appears to be little consistency in the actual definition of <italic>granuloma</italic> in these case reports; some authors seem to call every solitary nodule a <italic>granuloma</italic>, whereas others use <italic>polymorphonuclear foreign body type giant cells</italic>. The pathology of single nodules is different from that of true granulomatous inflammation, which is a systemic response (type IV hypersensitivity reaction). In a true granulomatous process, all sites that were originally injected with filler material appear adversely affected at the same time. If 4 sites on the patient were injected, then all 4 sites typically are involved at presentation. Solitary nodules have multiple possible causes, and if only 1 of several injected sites is affected, one of the alternative explanations should be considered. In other words, this appears to be a systemic process. Thus, it is likely an error in most cases to call a solitary nodule a “granulomatous lesion” because it is not typically pathologically verified as granulomatous inflammation.</p>
<p>The treatment of granulomatous inflammation should begin with an investigation of what agents have been injected. From there, the physician must decide the best pathway to success. Unfortunately, removal of the product that has been diffusely injected into vital structures such as the lips is neither practical nor desirable. The options, then, consist of methods to control the inflammation and halt the process. Once the diagnosis of granulomatous inflammation has been made as a result of treatment history, physical and, if possible, tissue biopsy, options for treatment are serial injection with cortisone or trials with various drugs. The author has found some success in treatment of these lesions with graduated injections of triamcinolone acetonide, starting with intralesional injections of 0.1 mL of a 10-mg/mL solution and then increasing the concentration to 20 mg/mL and 40 mg/mL with repeated injections until effective. Treatment should occur approximately every 4 weeks, and the amount injected should be carefully controlled to prevent posttreatment soft tissue atrophy. Another possible remedy may be 5-florouracil,<sup><xref ref-type="bibr" rid="bibr32-1090820X13484492">32</xref>,<xref ref-type="bibr" rid="bibr148-1090820X13484492">148</xref></sup> but the author has used this only once and is therefore not qualified to discuss its proper administration. The multitude of warnings on the label, as well as the requirement for safe use and disposal of 5-florouracil products, may also discourage others from utilizing it as a first-line choice.</p>
</sec>
</sec>
<sec id="section10-1090820X13484492" sec-type="conclusions">
<title>Conclusions</title>
<p>In this article, common technical errors in the use of dermal fillers and typical inflammatory complications (both immune and those caused by infectious agents) were reviewed. The prevalence of these complications tends to decrease as clinical experience accumulates. Hyaluronic acid dermal fillers have the advantage of being easily treatable with HYAL, which clinicians are encouraged to have readily available. Reversible filler agents have favorable properties in comparison to permanent, irreversible fillers for the treatment of vital facial structures. Avoidance of minor complications after filler procedures can be accomplished with technical “best practices” and detailed anatomical education. Biofilms may play a role in the development of nodules, but surgical preparation and good sterile technique may reduce the incidence of these complications. Detailed knowledge of tissue planes in the periorbital region will reduce the incidence of accidental retroseptal injection, or injection anterior to the orbitomalar septum (which causes premalar edema). Importantly, being prepared for emergencies should reduce the severity of adverse outcomes due to improper injection of HA and other filler products.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Disclosures</label>
<p>The author is a medical director, paid consultant, and a member of the speakers bureau for Merz Pharma Canada Inc (Burlington, Ontario), Allergan Canada Inc (Markham, Ontario), Medicis Aesthetics Canada Ltd (Toronto, Ontario), Ethicon Endo-Surgery Inc (Cincinnati, Ohio), and Baxter International Inc (Deerfield, Illinois).</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author received no financial support for the research, authorship, and publication of this article.</p>
</fn>
</fn-group>
<notes>
<fn-group>
<fn fn-type="other" id="fn1-1090820X13484492">
<label>*</label>
<p>References <xref ref-type="bibr" rid="bibr19-1090820X13484492">19</xref>, <xref ref-type="bibr" rid="bibr20-1090820X13484492">20</xref>, <xref ref-type="bibr" rid="bibr22-1090820X13484492">22</xref>, <xref ref-type="bibr" rid="bibr24-1090820X13484492">24</xref>, <xref ref-type="bibr" rid="bibr26-1090820X13484492">26</xref>, <xref ref-type="bibr" rid="bibr27-1090820X13484492">27</xref>, <xref ref-type="bibr" rid="bibr35-1090820X13484492">35</xref>, <xref ref-type="bibr" rid="bibr69-1090820X13484492">69</xref><xref ref-type="bibr" rid="bibr70-1090820X13484492"/><xref ref-type="bibr" rid="bibr71-1090820X13484492"/><xref ref-type="bibr" rid="bibr72-1090820X13484492"/><xref ref-type="bibr" rid="bibr73-1090820X13484492"/><xref ref-type="bibr" rid="bibr74-1090820X13484492"/><xref ref-type="bibr" rid="bibr75-1090820X13484492"/><xref ref-type="bibr" rid="bibr76-1090820X13484492"/><xref ref-type="bibr" rid="bibr77-1090820X13484492"/><xref ref-type="bibr" rid="bibr78-1090820X13484492"/><xref ref-type="bibr" rid="bibr79-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr80-1090820X13484492">80</xref>.</p>
</fn>
<fn fn-type="other" id="fn2-1090820X13484492">
<label>†</label>
<p>References <xref ref-type="bibr" rid="bibr98-1090820X13484492">98</xref>, <xref ref-type="bibr" rid="bibr101-1090820X13484492">101</xref>, <xref ref-type="bibr" rid="bibr104-1090820X13484492">104</xref>, <xref ref-type="bibr" rid="bibr119-1090820X13484492">119</xref>, <xref ref-type="bibr" rid="bibr121-1090820X13484492">121</xref>, <xref ref-type="bibr" rid="bibr122-1090820X13484492">122</xref>, <xref ref-type="bibr" rid="bibr125-1090820X13484492">125</xref>.</p>
</fn>
<fn fn-type="other" id="fn3-1090820X13484492">
<label>‡</label>
<p>References <xref ref-type="bibr" rid="bibr34-1090820X13484492">34</xref>, <xref ref-type="bibr" rid="bibr36-1090820X13484492">36</xref><xref ref-type="bibr" rid="bibr37-1090820X13484492"/><xref ref-type="bibr" rid="bibr38-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr39-1090820X13484492">39</xref>, <xref ref-type="bibr" rid="bibr99-1090820X13484492">99</xref>, <xref ref-type="bibr" rid="bibr134-1090820X13484492">134</xref>, <xref ref-type="bibr" rid="bibr147-1090820X13484492">147</xref><xref ref-type="bibr" rid="bibr148-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr149-1090820X13484492">149</xref>.</p>
</fn>
<fn fn-type="other" id="fn4-1090820X13484492">
<label>§</label>
<p>References <xref ref-type="bibr" rid="bibr12-1090820X13484492">12</xref>, <xref ref-type="bibr" rid="bibr13-1090820X13484492">13</xref>, <xref ref-type="bibr" rid="bibr15-1090820X13484492">15</xref>, <xref ref-type="bibr" rid="bibr25-1090820X13484492">25</xref>, <xref ref-type="bibr" rid="bibr30-1090820X13484492">30</xref><xref ref-type="bibr" rid="bibr31-1090820X13484492"/><xref ref-type="bibr" rid="bibr32-1090820X13484492"/><xref ref-type="bibr" rid="bibr33-1090820X13484492"/><xref ref-type="bibr" rid="bibr34-1090820X13484492"/><xref ref-type="bibr" rid="bibr35-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr36-1090820X13484492">36</xref>, <xref ref-type="bibr" rid="bibr38-1090820X13484492">38</xref>, <xref ref-type="bibr" rid="bibr39-1090820X13484492">39</xref>, <xref ref-type="bibr" rid="bibr41-1090820X13484492">41</xref>, <xref ref-type="bibr" rid="bibr95-1090820X13484492">95</xref>, <xref ref-type="bibr" rid="bibr96-1090820X13484492">96</xref>, <xref ref-type="bibr" rid="bibr100-1090820X13484492">100</xref>, <xref ref-type="bibr" rid="bibr102-1090820X13484492">102</xref>, <xref ref-type="bibr" rid="bibr104-1090820X13484492">104</xref><xref ref-type="bibr" rid="bibr105-1090820X13484492"/><xref ref-type="bibr" rid="bibr106-1090820X13484492"/><xref ref-type="bibr" rid="bibr107-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr108-1090820X13484492">108</xref>, <xref ref-type="bibr" rid="bibr110-1090820X13484492">110</xref>, <xref ref-type="bibr" rid="bibr113-1090820X13484492">113</xref>, <xref ref-type="bibr" rid="bibr117-1090820X13484492">117</xref>, <xref ref-type="bibr" rid="bibr119-1090820X13484492">119</xref>, <xref ref-type="bibr" rid="bibr120-1090820X13484492">120</xref>, <xref ref-type="bibr" rid="bibr123-1090820X13484492">123</xref>, <xref ref-type="bibr" rid="bibr124-1090820X13484492">124</xref>, <xref ref-type="bibr" rid="bibr127-1090820X13484492">127</xref>, <xref ref-type="bibr" rid="bibr128-1090820X13484492">128</xref>, <xref ref-type="bibr" rid="bibr158-1090820X13484492">158</xref>, <xref ref-type="bibr" rid="bibr162-1090820X13484492">162</xref><xref ref-type="bibr" rid="bibr163-1090820X13484492"/><xref ref-type="bibr" rid="bibr164-1090820X13484492"/><xref ref-type="bibr" rid="bibr165-1090820X13484492"/><xref ref-type="bibr" rid="bibr166-1090820X13484492"/><xref ref-type="bibr" rid="bibr167-1090820X13484492"/><xref ref-type="bibr" rid="bibr168-1090820X13484492"/><xref ref-type="bibr" rid="bibr169-1090820X13484492"/><xref ref-type="bibr" rid="bibr170-1090820X13484492"/><xref ref-type="bibr" rid="bibr171-1090820X13484492"/><xref ref-type="bibr" rid="bibr172-1090820X13484492"/><xref ref-type="bibr" rid="bibr173-1090820X13484492"/><xref ref-type="bibr" rid="bibr174-1090820X13484492"/><xref ref-type="bibr" rid="bibr175-1090820X13484492"/><xref ref-type="bibr" rid="bibr176-1090820X13484492"/><xref ref-type="bibr" rid="bibr177-1090820X13484492"/><xref ref-type="bibr" rid="bibr178-1090820X13484492"/><xref ref-type="bibr" rid="bibr179-1090820X13484492"/><xref ref-type="bibr" rid="bibr180-1090820X13484492"/><xref ref-type="bibr" rid="bibr181-1090820X13484492"/><xref ref-type="bibr" rid="bibr182-1090820X13484492"/><xref ref-type="bibr" rid="bibr183-1090820X13484492"/><xref ref-type="bibr" rid="bibr184-1090820X13484492"/><xref ref-type="bibr" rid="bibr185-1090820X13484492"/><xref ref-type="bibr" rid="bibr186-1090820X13484492"/><xref ref-type="bibr" rid="bibr187-1090820X13484492"/><xref ref-type="bibr" rid="bibr188-1090820X13484492"/><xref ref-type="bibr" rid="bibr189-1090820X13484492"/><xref ref-type="bibr" rid="bibr190-1090820X13484492"/><xref ref-type="bibr" rid="bibr191-1090820X13484492"/><xref ref-type="bibr" rid="bibr192-1090820X13484492"/><xref ref-type="bibr" rid="bibr193-1090820X13484492"/><xref ref-type="bibr" rid="bibr194-1090820X13484492"/><xref ref-type="bibr" rid="bibr195-1090820X13484492"/><xref ref-type="bibr" rid="bibr196-1090820X13484492"/><xref ref-type="bibr" rid="bibr197-1090820X13484492"/><xref ref-type="bibr" rid="bibr198-1090820X13484492"/><xref ref-type="bibr" rid="bibr199-1090820X13484492"/><xref ref-type="bibr" rid="bibr200-1090820X13484492"/><xref ref-type="bibr" rid="bibr201-1090820X13484492"/><xref ref-type="bibr" rid="bibr202-1090820X13484492"/><xref ref-type="bibr" rid="bibr203-1090820X13484492"/><xref ref-type="bibr" rid="bibr204-1090820X13484492"/><xref ref-type="bibr" rid="bibr205-1090820X13484492"/><xref ref-type="bibr" rid="bibr206-1090820X13484492"/><xref ref-type="bibr" rid="bibr207-1090820X13484492"/><xref ref-type="bibr" rid="bibr208-1090820X13484492"/><xref ref-type="bibr" rid="bibr209-1090820X13484492"/><xref ref-type="bibr" rid="bibr210-1090820X13484492"/><xref ref-type="bibr" rid="bibr211-1090820X13484492"/><xref ref-type="bibr" rid="bibr212-1090820X13484492"/><xref ref-type="bibr" rid="bibr213-1090820X13484492"/><xref ref-type="bibr" rid="bibr214-1090820X13484492"/><xref ref-type="bibr" rid="bibr215-1090820X13484492"/><xref ref-type="bibr" rid="bibr216-1090820X13484492"/><xref ref-type="bibr" rid="bibr218-1090820X13484492"/><xref ref-type="bibr" rid="bibr219-1090820X13484492"/><xref ref-type="bibr" rid="bibr220-1090820X13484492"/><xref ref-type="bibr" rid="bibr221-1090820X13484492"/><xref ref-type="bibr" rid="bibr222-1090820X13484492"/><xref ref-type="bibr" rid="bibr223-1090820X13484492"/><xref ref-type="bibr" rid="bibr224-1090820X13484492"/><xref ref-type="bibr" rid="bibr225-1090820X13484492"/><xref ref-type="bibr" rid="bibr226-1090820X13484492"/><xref ref-type="bibr" rid="bibr227-1090820X13484492"/><xref ref-type="bibr" rid="bibr228-1090820X13484492"/><xref ref-type="bibr" rid="bibr229-1090820X13484492"/><xref ref-type="bibr" rid="bibr230-1090820X13484492"/><xref ref-type="bibr" rid="bibr231-1090820X13484492"/><xref ref-type="bibr" rid="bibr232-1090820X13484492"/><xref ref-type="bibr" rid="bibr233-1090820X13484492"/><xref ref-type="bibr" rid="bibr234-1090820X13484492"/><xref ref-type="bibr" rid="bibr235-1090820X13484492"/>-<xref ref-type="bibr" rid="bibr236-1090820X13484492">236</xref>.</p>
</fn>
</fn-group>
</notes>
<ref-list>
<title>References</title>
<ref id="bibr1-1090820X13484492">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>K</given-names></name>
<name><surname>Palmer</surname><given-names>JW</given-names></name>
</person-group>. <article-title>The polysaccharide of the vitreous humour</article-title>. <source>J Biol Chem</source>. <year>1934</year>;<volume>107</volume>:<fpage>629</fpage>-<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr2-1090820X13484492">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Garg</surname><given-names>HG</given-names></name>
<name><surname>Hales</surname><given-names>CA</given-names></name>
</person-group>. <source>Chemistry and Biology of Hyaluronan</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2004</year>.</citation>
</ref>
<ref id="bibr3-1090820X13484492">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nusgens</surname><given-names>BV</given-names></name>
</person-group>. <article-title>[Hyaluronic acid and extracellular matrix: a primitive molecule? [in French]</article-title>. <source>Ann Dermatol Venereol</source>. <year>2010</year>;<volume>137</volume>(<supplement>suppl 1</supplement>):<fpage>S3</fpage>-<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr4-1090820X13484492">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ascher</surname><given-names>B</given-names></name>
<name><surname>Cerceau</surname><given-names>M</given-names></name>
<name><surname>Baspeyras</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Soft tissue filling with hyaluronic acid [in French]</article-title>. <source>Ann Chir Plast Esthet</source>. <year>2004</year>;<volume>49</volume>:<fpage>465</fpage>-<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr5-1090820X13484492">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>JR</given-names></name>
<name><surname>Laurent</surname><given-names>TC</given-names></name>
<name><surname>Laurent</surname><given-names>UB</given-names></name>
</person-group>. <article-title>Hyaluronan: its nature, distribution, functions and turnover</article-title>. <source>J Intern Med</source>. <year>1997</year>;<volume>242</volume>:<fpage>27</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr6-1090820X13484492">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>JR</given-names></name>
<name><surname>Dahl</surname><given-names>LB</given-names></name>
<name><surname>Kimpton</surname><given-names>WG</given-names></name><etal/>
</person-group>. <article-title>Elimination and subsequent metabolism of circulating hyaluronic acid in the fetus</article-title>. <source>J Dev Physiol</source>. <year>1989</year>;<volume>11</volume>:<fpage>235</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr7-1090820X13484492">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>JR</given-names></name>
<name><surname>Laurent</surname><given-names>TC</given-names></name>
</person-group>. <article-title>Turnover and metabolism of hyaluronan</article-title>. <source>Ciba Found Symp</source>. <year>1989</year>;<volume>143</volume>:<fpage>41</fpage>-<lpage>53</lpage>; discussion <fpage>53</fpage>-<lpage>59</lpage>, <fpage>281</fpage>-<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr8-1090820X13484492">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laurent</surname><given-names>TC</given-names></name>
</person-group>. <article-title>Biochemistry of hyaluronan</article-title>. <source>Acta Otolaryngol Suppl</source>. <year>1987</year>;<volume>442</volume>:<fpage>7</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr9-1090820X13484492">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laurent</surname><given-names>TC</given-names></name>
<name><surname>Dahl</surname><given-names>IM</given-names></name>
<name><surname>Dahl</surname><given-names>LB</given-names></name><etal/>
</person-group>. <article-title>The catabolic fate of hyaluronic acid</article-title>. <source>Connect Tissue Res</source>. <year>1986</year>;<volume>15</volume>:<fpage>33</fpage>-<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr10-1090820X13484492">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fraser</surname><given-names>JR</given-names></name>
<name><surname>Laurent</surname><given-names>TC</given-names></name>
<name><surname>Engstrom-Laurent</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Elimination of hyaluronic acid from the blood stream in the human</article-title>. <source>Clin Exp Pharmacol Physiol</source>. <year>1984</year>;<volume>11</volume>:<fpage>17</fpage>-<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr11-1090820X13484492">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tezel</surname><given-names>A</given-names></name>
<name><surname>Fredrickson</surname><given-names>GH</given-names></name>
</person-group>. <article-title>The science of hyaluronic acid dermal fillers</article-title>. <source>J Cosmet Laser Ther</source>. <year>2008</year>;<volume>10</volume>:<fpage>35</fpage>-<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr12-1090820X13484492">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowe</surname><given-names>NJ</given-names></name>
<name><surname>Maxwell</surname><given-names>CA</given-names></name>
<name><surname>Patnaik</surname><given-names>R</given-names></name>
</person-group>. <article-title>Adverse reactions to dermal fillers: review</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>1616</fpage>-<lpage>1625</lpage>.</citation>
</ref>
<ref id="bibr13-1090820X13484492">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curcio</surname><given-names>NM</given-names></name>
<name><surname>Parish</surname><given-names>LC</given-names></name>
</person-group>. <article-title>Injectable fillers: an American perspective</article-title>. <source>G Ital Dermatol Venereol</source>. <year>2009</year>;<volume>144</volume>:<fpage>271</fpage>-<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr14-1090820X13484492">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>DA</given-names></name>
<name><surname>Segall</surname><given-names>L</given-names></name>
</person-group>. <article-title>Review of non-FDA-approved fillers</article-title>. <source>Facial Plast Surg Clin North Am</source>. <year>2007</year>;<volume>15</volume>:<fpage>239</fpage>-<lpage>246</lpage>, <fpage>vii</fpage>.</citation>
</ref>
<ref id="bibr15-1090820X13484492">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kontis</surname><given-names>TC</given-names></name>
<name><surname>Rivkin</surname><given-names>A</given-names></name>
</person-group>. <article-title>The history of injectable facial fillers</article-title>. <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>67</fpage>-<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr16-1090820X13484492">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wesley</surname><given-names>NO</given-names></name>
<name><surname>Dover</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The filler revolution: a six-year retrospective</article-title>. <source>J Drugs Dermatol</source>. <year>2009</year>;<volume>8</volume>:<fpage>903</fpage>-<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr17-1090820X13484492">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rivkin</surname><given-names>A</given-names></name>
</person-group>. <article-title>New fillers under consideration: what is the future of injectable aesthetics?</article-title> <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>120</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr18-1090820X13484492">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Breakthroughs in US dermal fillers for facial soft-tissue augmentation</article-title>. <source>J Cosmet Laser Ther</source>. <year>2009</year>;<volume>11</volume>:<fpage>240</fpage>-<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr19-1090820X13484492">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>KC</given-names></name>
<name><surname>Reversible</surname><given-names>vs</given-names></name>
</person-group>. <article-title>nonreversible fillers in facial aesthetics: concerns and considerations</article-title>. <source>Dermatol Online J</source>. <year>2008</year>;<volume>14</volume>:<fpage>3</fpage>.</citation>
</ref>
<ref id="bibr20-1090820X13484492">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>TH</given-names></name>
<name><surname>Seo</surname><given-names>SW</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name><etal/>
</person-group>. <article-title>Clinical experience with hyaluronic acid–filler complications</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2011</year>;<volume>64</volume>:<fpage>892</fpage>-<lpage>896</lpage>.</citation>
</ref>
<ref id="bibr21-1090820X13484492">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Menon</surname><given-names>H</given-names></name>
<name><surname>Thomas</surname><given-names>M</given-names></name>
<name><surname>D’Silva</surname><given-names>J</given-names></name>
</person-group>. <article-title>Low dose of hyaluronidase to treat over correction by HA filler—a case report</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2010</year>;<volume>63</volume>:<fpage>e416</fpage>-<lpage>e417</lpage>.</citation>
</ref>
<ref id="bibr22-1090820X13484492">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rzany</surname><given-names>B</given-names></name>
<name><surname>Becker-Wegerich</surname><given-names>P</given-names></name>
<name><surname>Bachmann</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Hyaluronidase in the correction of hyaluronic acid-based fillers: a review and a recommendation for use</article-title>. <source>J Cosmet Dermatol</source>. <year>2009</year>;<volume>8</volume>:<fpage>317</fpage>-<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr23-1090820X13484492">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Brody</surname><given-names>HJ</given-names></name>
<name><surname>Carruthers</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid</article-title>. <source>J Cosmet Laser Ther</source>. <year>2007</year>;<volume>9</volume>:<fpage>182</fpage>-<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr24-1090820X13484492">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pierre</surname><given-names>A</given-names></name>
<name><surname>Levy</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Hyaluronidase offers an efficacious treatment for inaesthetic hyaluronic acid overcorrection</article-title>. <source>J Cosmet Dermatol</source>. <year>2007</year>;<volume>6</volume>:<fpage>159</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr25-1090820X13484492">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brody</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>893</fpage>-<lpage>897</lpage>.</citation>
</ref>
<ref id="bibr26-1090820X13484492">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lambros</surname><given-names>V</given-names></name>
</person-group>. <article-title>The use of hyaluronidase to reverse the effects of hyaluronic acid filler</article-title>. <source>Plast Reconstr Surg</source>. <year>2004</year>;<volume>114</volume>:<fpage>277</fpage>.</citation>
</ref>
<ref id="bibr27-1090820X13484492">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soparkar</surname><given-names>CN</given-names></name>
<name><surname>Patrinely</surname><given-names>JR</given-names></name>
<name><surname>Tschen</surname><given-names>J</given-names></name>
</person-group>. <article-title>Erasing Restylane</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2004</year>;<volume>20</volume>:<fpage>317</fpage>-<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr28-1090820X13484492">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>TH</given-names></name>
<name><surname>Seo</surname><given-names>SW</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name><etal/>
</person-group>. <article-title>Clinical outcome in a series of 173 cases of foreign body granuloma: improved outcomes with a novel surgical technique</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2012</year>;<volume>65</volume>:<fpage>29</fpage>-<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr29-1090820X13484492">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>TH</given-names></name>
<name><surname>Seo</surname><given-names>SW</given-names></name>
<name><surname>Kim</surname><given-names>JK</given-names></name><etal/>
</person-group>. <article-title>Clinical experience with polymethylmethacrylate microsphere filler complications</article-title>. <source>Aesthetic Plast Surg</source>. <year>2012</year>;<volume>36</volume>:<fpage>421</fpage>-<lpage>426</lpage>.</citation>
</ref>
<ref id="bibr30-1090820X13484492">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
</person-group>. <article-title>Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options</article-title>. <source>Plast Reconstr Surg</source>. <year>2009</year>;<volume>123</volume>:<fpage>1864</fpage>-<lpage>1873</lpage>.</citation>
</ref>
<ref id="bibr31-1090820X13484492">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stewart</surname><given-names>DB</given-names></name>
<name><surname>Morganroth</surname><given-names>GS</given-names></name>
<name><surname>Mooney</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Management of visible granulomas following periorbital injection of poly-L-lactic acid</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2007</year>;<volume>23</volume>:<fpage>298</fpage>-<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr32-1090820X13484492">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Rullan</surname><given-names>PP</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
</person-group>. <article-title>Avoiding and treating dermal filler complications</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>118</volume>:<fpage>92S</fpage>-<lpage>107S</lpage>.</citation>
</ref>
<ref id="bibr33-1090820X13484492">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicolau</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Long-lasting and permanent fillers: biomaterial influence over host tissue response</article-title>. <source>Plast Reconstr Surg</source>. <year>2007</year>;<volume>119</volume>:<fpage>2271</fpage>-<lpage>2286</lpage>.</citation>
</ref>
<ref id="bibr34-1090820X13484492">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rohrich</surname><given-names>RJ</given-names></name>
<name><surname>Monheit</surname><given-names>G</given-names></name>
<name><surname>Nguyen</surname><given-names>AT</given-names></name><etal/>
</person-group>. <article-title>Soft-tissue filler complications: the important role of biofilms</article-title>. <source>Plast Reconstr Surg</source>. <year>2010</year>;<volume>125</volume>:<fpage>1250</fpage>-<lpage>1256</lpage>.</citation>
</ref>
<ref id="bibr35-1090820X13484492">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
<name><surname>Coleman</surname><given-names>WP</given-names><suffix>III</suffix></name>
<name><surname>Glogau</surname><given-names>RG</given-names></name>
</person-group>. <article-title>Recommendations and treatment options for nodules and other filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1667</fpage>-<lpage>1671</lpage>.</citation>
</ref>
<ref id="bibr36-1090820X13484492">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>LH</given-names></name>
</person-group>. <article-title>Host tissue interaction, fate, and risks of degradable and nondegradable gel fillers</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1612</fpage>-<lpage>1619</lpage>.</citation>
</ref>
<ref id="bibr37-1090820X13484492">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bjarnsholt</surname><given-names>T</given-names></name>
<name><surname>Tolker-Nielsen</surname><given-names>T</given-names></name>
<name><surname>Givskov</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Detection of bacteria by fluorescence in situ hybridization in culture-negative soft tissue filler lesions</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1620</fpage>-<lpage>1624</lpage>.</citation>
</ref>
<ref id="bibr38-1090820X13484492">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bentkover</surname><given-names>SH</given-names></name>
</person-group>. <article-title>The biology of facial fillers</article-title>. <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>73</fpage>-<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr39-1090820X13484492">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>L</given-names></name>
</person-group>. <article-title>Normal and pathologic tissue reactions to soft tissue gel fillers</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S168</fpage>-<lpage>S175</lpage>.</citation>
</ref>
<ref id="bibr40-1090820X13484492">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bachmann</surname><given-names>F</given-names></name>
<name><surname>Erdmann</surname><given-names>R</given-names></name>
<name><surname>Hartmann</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions caused by consecutive injections of different fillers in the same facial region: risk assessment based on the results from the Injectable Filler Safety study</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2011</year>;<volume>25</volume>:<fpage>902</fpage>-<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr41-1090820X13484492">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Hazan-Gauthier</surname><given-names>N</given-names></name>
<name><surname>Lemperle</surname><given-names>M</given-names></name>
</person-group>. <article-title>PMMA microspheres (Artecoll) for skin and soft-tissue augmentation, part II: clinical investigations</article-title>. <source>Plast Reconstr Surg</source>. <year>1995</year>;<volume>96</volume>:<fpage>627</fpage>-<lpage>634</lpage>.</citation>
</ref>
<ref id="bibr42-1090820X13484492">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laeschke</surname><given-names>K</given-names></name>
</person-group>. <article-title>Biocompatibility of microparticles into soft tissue fillers</article-title>. <source>Semin Cutan Med Surg</source>. <year>2004</year>;<volume>23</volume>:<fpage>214</fpage>-<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr43-1090820X13484492">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>K</given-names></name>
</person-group>. <article-title>The biological significance of hyaluronic acid and hyaluronidase</article-title>. <source>Physiol Rev</source>. <year>1947</year>;<volume>27</volume>:<fpage>335</fpage>-<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr44-1090820X13484492">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Atkinson</surname><given-names>WS</given-names></name>
</person-group>. <article-title>Use of hyaluronidase with local anesthesia in ophthalmology: preliminary report</article-title>. <source>Arch Ophthal</source>. <year>1949</year>;<volume>42</volume>:<fpage>628</fpage>-<lpage>633</lpage>.</citation>
</ref>
<ref id="bibr45-1090820X13484492">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hechter</surname><given-names>O</given-names></name>
<name><surname>Dopkeen</surname><given-names>SK</given-names></name>
<name><surname>Yudell</surname><given-names>MH</given-names></name>
</person-group>. <article-title>The clinical use of hyaluronidase in hypodermoclysis</article-title>. <source>J Pediatr</source>. <year>1947</year>;<volume>30</volume>:<fpage>645</fpage>-<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr46-1090820X13484492">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greenberg</surname><given-names>BE</given-names></name>
<name><surname>Gargill</surname><given-names>SL</given-names></name>
</person-group>. <article-title>The relation of hyaluronidase in the seminal fluid to fertility</article-title>. <source>Hum Fertil</source>. <year>1946</year>;<volume>11</volume>:<fpage>1</fpage>.</citation>
</ref>
<ref id="bibr47-1090820X13484492">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurzrok</surname><given-names>R</given-names></name>
</person-group>. <article-title>Hyaluronidase; an enzyme essential for human fertility</article-title>. <source>Manitoba Med Rev</source>. <year>1948</year>;<volume>28</volume>:<fpage>216</fpage>.</citation>
</ref>
<ref id="bibr48-1090820X13484492">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Riisfeldt</surname><given-names>O</given-names></name>
</person-group>. <article-title>Studies on hyaluronidase in semen from men in sterile and fertile marriages</article-title>. <source>Ann Ostet Ginecol</source>. <year>1951</year>;<volume>73</volume>:<fpage>853</fpage>-<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr49-1090820X13484492">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jadin</surname><given-names>L</given-names></name>
<name><surname>Bookbinder</surname><given-names>LH</given-names></name>
<name><surname>Frost</surname><given-names>GI</given-names></name>
</person-group>. <article-title>A comprehensive model of hyaluronan turnover in the mouse</article-title>. <source>Matrix Biol</source>. <year>2012</year>;<volume>31</volume>:<fpage>81</fpage>-<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr50-1090820X13484492">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hofinger</surname><given-names>ES</given-names></name>
<name><surname>Hoechstetter</surname><given-names>J</given-names></name>
<name><surname>Oettl</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Isoenzyme-specific differences in the degradation of hyaluronic acid by mammalian-type hyaluronidases</article-title>. <source>Glycoconj J</source>. <year>2008</year>;<volume>25</volume>:<fpage>101</fpage>-<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr51-1090820X13484492">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delaere</surname><given-names>L</given-names></name>
<name><surname>Zeyen</surname><given-names>T</given-names></name>
<name><surname>Foets</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Allergic reaction to hyaluronidase after retrobulbar anaesthesia: a case series and review</article-title>. <source>Int Ophthalmol</source>. <year>2009</year>;<volume>29</volume>:<fpage>521</fpage>-<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr52-1090820X13484492">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leibovitch</surname><given-names>I</given-names></name>
<name><surname>Tamblyn</surname><given-names>D</given-names></name>
<name><surname>Casson</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Allergic reaction to hyaluronidase: a rare cause of orbital inflammation after cataract surgery</article-title>. <source>Graefes Arch Clin Exp Ophthalmol</source>. <year>2006</year>;<volume>244</volume>:<fpage>944</fpage>-<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr53-1090820X13484492">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patil</surname><given-names>B</given-names></name>
<name><surname>Agius-Fernandez</surname><given-names>A</given-names></name>
<name><surname>Worstmann</surname><given-names>T</given-names></name>
</person-group>. <article-title>Hyaluronidase allergy after peribulbar anesthesia with orbital inflammation</article-title>. <source>J Cataract Refract Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>1480</fpage>-<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr54-1090820X13484492">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Escolano</surname><given-names>F</given-names></name>
<name><surname>Pares</surname><given-names>N</given-names></name>
<name><surname>Gonzalez</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Allergic reaction to hyaluronidase in cataract surgery</article-title>. <source>Eur J Anaesthesiol</source>. <year>2005</year>;<volume>22</volume>:<fpage>729</fpage>-<lpage>730</lpage>.</citation>
</ref>
<ref id="bibr55-1090820X13484492">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quhill</surname><given-names>F</given-names></name>
<name><surname>Bowling</surname><given-names>B</given-names></name>
<name><surname>Packard</surname><given-names>RB</given-names></name>
</person-group>. <article-title>Hyaluronidase allergy after peribulbar anesthesia with orbital inflammation</article-title>. <source>J Cataract Refract Surg</source>. <year>2004</year>;<volume>30</volume>:<fpage>916</fpage>-<lpage>917</lpage>.</citation>
</ref>
<ref id="bibr56-1090820X13484492">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eberhart</surname><given-names>AH</given-names></name>
<name><surname>Weiler</surname><given-names>CR</given-names></name>
<name><surname>Erie</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Angioedema related to the use of hyaluronidase in cataract surgery</article-title>. <source>Am J Ophthalmol</source>. <year>2004</year>;<volume>138</volume>:<fpage>142</fpage>-<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr57-1090820X13484492">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicholson</surname><given-names>G</given-names></name>
<name><surname>Hall</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Allergic reaction to hyaluronidase after a peribulbar injection</article-title>. <source>Anaesthesia</source>. <year>2003</year>;<volume>58</volume>:<fpage>814</fpage>-<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr58-1090820X13484492">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahluwalia</surname><given-names>HS</given-names></name>
<name><surname>Lukaris</surname><given-names>A</given-names></name>
<name><surname>Lane</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Delayed allergic reaction to hyaluronidase: a rare sequel to cataract surgery</article-title>. <source>Eye</source>. <year>2003</year>;<volume>17</volume>:<fpage>263</fpage>-<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr59-1090820X13484492">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>A</given-names></name>
<name><surname>McLure</surname><given-names>HA</given-names></name>
<name><surname>Dabbs</surname><given-names>TR</given-names></name>
</person-group>. <article-title>Allergic reaction to hyaluronidase after a peribulbar injection</article-title>. <source>Anaesthesia</source>. <year>2003</year>;<volume>58</volume>:<fpage>493</fpage>-<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr60-1090820X13484492">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kirby</surname><given-names>B</given-names></name>
<name><surname>Butt</surname><given-names>A</given-names></name>
<name><surname>Morrison</surname><given-names>AM</given-names></name><etal/>
</person-group>. <article-title>Type I allergic reaction to hyaluronidase during ophthalmic surgery</article-title>. <source>Contact Dermatitis</source>. <year>2001</year>;<volume>44</volume>:<fpage>52</fpage>.</citation>
</ref>
<ref id="bibr61-1090820X13484492">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Minning</surname><given-names>CA</given-names><suffix>Jr.</suffix></name>
</person-group>. <article-title>Hyaluronidase allergy simulating expulsive choroidal hemorrhage</article-title>. <source>Arch Ophthalmol</source>. <year>1994</year>;<volume>112</volume>:<fpage>585</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr62-1090820X13484492">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sakamoto</surname><given-names>K</given-names></name>
<name><surname>Nagai</surname><given-names>H</given-names></name>
<name><surname>Koda</surname><given-names>A</given-names></name>
</person-group>. <article-title>Role of hyaluronidase in immediate hypersensitivity reaction</article-title>. <source>Immunopharmacology</source>. <year>1980</year>;<volume>2</volume>:<fpage>139</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr63-1090820X13484492">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richter</surname><given-names>G</given-names></name>
<name><surname>Richter</surname><given-names>W</given-names></name>
</person-group>. <article-title>The risk of intravenous treatment with hyaluronidase from a dermatological viewpoint [in German]</article-title>. <source>Dermatol Monatschr</source>. <year>1975</year>;<volume>161</volume>:<fpage>952</fpage>-<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr64-1090820X13484492">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McEwen</surname><given-names>LM</given-names></name>
<name><surname>Starr</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Enzyme-potentiated hyposensitisation, I: the effect of pre-treatment with -glucuronidase, hyaluronidase, and antigen on anaphylactic sensitivity of guinea-pigs, rats and mice</article-title>. <source>Int Arch Allergy Appl Immunol</source>. <year>1972</year>;<volume>42</volume>:<fpage>152</fpage>-<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr65-1090820X13484492">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kind</surname><given-names>LS</given-names></name>
<name><surname>Roffler</surname><given-names>S</given-names></name>
</person-group>. <article-title>Allergic reactions to hyaluronidase</article-title>. <source>Proc Soc Exp Biol Med</source>. <year>1961</year>;<volume>106</volume>:<fpage>734</fpage>-<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr66-1090820X13484492">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ebo</surname><given-names>DG</given-names></name>
<name><surname>Goossens</surname><given-names>S</given-names></name>
<name><surname>Opsomer</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Flow-assisted diagnosis of anaphylaxis to hyaluronidase</article-title>. <source>Allergy</source>. <year>2005</year>;<volume>60</volume>:<fpage>1333</fpage>-<lpage>1334</lpage>.</citation>
</ref>
<ref id="bibr67-1090820X13484492">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>U</given-names></name>
<name><surname>Bircher</surname><given-names>A</given-names></name>
<name><surname>Bischof</surname><given-names>M</given-names></name>
</person-group>. <article-title>Allergic angioedema after local dental anesthesia and a hyaluronidase-containing preanesthetic injection solution [in German]</article-title>. <source>Schweiz Med Wochenschr</source>. <year>1986</year>;<volume>116</volume>:<fpage>1810</fpage>-<lpage>1813</lpage>.</citation>
</ref>
<ref id="bibr68-1090820X13484492">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>HK</given-names></name>
<name><surname>Choi</surname><given-names>EJ</given-names></name>
<name><surname>Lee</surname><given-names>PB</given-names></name><etal/>
</person-group>. <article-title>Anaphylactic shock caused by the epidurally-administered hyalurinidase</article-title>. <source>Korean J Pain</source>. <year>2011</year>;<volume>24</volume>:<fpage>221</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr69-1090820X13484492">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morley</surname><given-names>AM</given-names></name>
<name><surname>Malhotra</surname><given-names>R</given-names></name>
</person-group>. <article-title>Use of hyaluronic acid filler for tear-trough rejuvenation as an alternative to lower eyelid surgery</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2011</year>;<volume>27</volume>:<fpage>69</fpage>-<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr70-1090820X13484492">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Dyke</surname><given-names>S</given-names></name>
<name><surname>Hays</surname><given-names>GP</given-names></name>
<name><surname>Caglia</surname><given-names>AE</given-names></name><etal/>
</person-group>. <article-title>Severe acute local reactions to a hyaluronic acid–derived dermal filler</article-title>. <source>J Clin Aesthetic Dermatol</source>. <year>2010</year>;<volume>3</volume>:<fpage>32</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr71-1090820X13484492">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skeie</surname><given-names>L</given-names></name>
<name><surname>Bugge</surname><given-names>H</given-names></name>
<name><surname>Negaard</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study</article-title>. <source>HIV Med</source>. <year>2010</year>;<volume>11</volume>:<fpage>170</fpage>-<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr72-1090820X13484492">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Menon</surname><given-names>H</given-names></name>
<name><surname>Thomas</surname><given-names>M</given-names></name>
<name><surname>D’Silva</surname><given-names>J</given-names></name>
</person-group>. <article-title>Low dose of hyaluronidase to treat over correction by HA filler—a case report</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2010</year>;<volume>63</volume>:<fpage>e416</fpage>-<lpage>e417</lpage>.</citation>
</ref>
<ref id="bibr73-1090820X13484492">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volpi</surname><given-names>N</given-names></name>
<name><surname>Schiller</surname><given-names>J</given-names></name>
<name><surname>Stern</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Role, metabolism, chemical modifications and applications of hyaluronan</article-title>. <source>Curr Med Chem</source>. <year>2009</year>;<volume>16</volume>:<fpage>1718</fpage>-<lpage>1745</lpage>.</citation>
</ref>
<ref id="bibr74-1090820X13484492">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sclafani</surname><given-names>AP</given-names></name>
<name><surname>Fagien</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of injectable soft tissue filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1672</fpage>-<lpage>1680</lpage>.</citation>
</ref>
<ref id="bibr75-1090820X13484492">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grunebaum</surname><given-names>LD</given-names></name>
<name><surname>Bogdan Allemann</surname><given-names>I</given-names></name>
<name><surname>Dayan</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>The risk of alar necrosis associated with dermal filler injection</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1635</fpage>-<lpage>1640</lpage>.</citation>
</ref>
<ref id="bibr76-1090820X13484492">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldman</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Pressure-induced migration of a permanent soft tissue filler</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>403</fpage>-<lpage>405</lpage>; discussion <fpage>405</fpage>-<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr77-1090820X13484492">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>SE</given-names></name>
</person-group>. <article-title>Clinical experience with filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1661</fpage>-<lpage>1666</lpage>.</citation>
</ref>
<ref id="bibr78-1090820X13484492">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Brody</surname><given-names>HJ</given-names></name>
<name><surname>Carruthers</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Hyaluronidase in the office: a necessity for every dermasurgeon that injects hyaluronic acid</article-title>. <source>J Cosmet Laser Ther</source>. <year>2007</year>;<volume>9</volume>:<fpage>182</fpage>-<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr79-1090820X13484492">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goldberg</surname><given-names>RA</given-names></name>
<name><surname>Fiaschetti</surname><given-names>D</given-names></name>
</person-group>. <article-title>Filling the periorbital hollows with hyaluronic acid gel: initial experience with 244 injections</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2006</year>;<volume>22</volume>:<fpage>335</fpage>-<lpage>341</lpage>; discussion <fpage>341</fpage>-<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr80-1090820X13484492">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glaich</surname><given-names>AS</given-names></name>
<name><surname>Cohen</surname><given-names>JL</given-names></name>
<name><surname>Goldberg</surname><given-names>LH</given-names></name>
</person-group>. <article-title>Injection necrosis of the glabella: protocol for prevention and treatment after use of dermal fillers</article-title>. <source>Dermatol Surg</source>. <year>2006</year>;<volume>32</volume>:<fpage>276</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr81-1090820X13484492">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Carruthers</surname><given-names>JD</given-names></name>
<name><surname>Carruthers</surname><given-names>A</given-names></name>
</person-group>. <article-title>Infraorbital hollow treatment by dermal fillers</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>:<fpage>1116</fpage>-<lpage>1119</lpage>.</citation>
</ref>
<ref id="bibr82-1090820X13484492">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>CL</given-names></name>
<name><surname>Stinnett</surname><given-names>SS</given-names></name>
<name><surname>Woodward</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Patient-preferred sites of Restylane injection in periocular and facial soft-tissue augmentation</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2008</year>;<volume>24</volume>:<fpage>117</fpage>-<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr83-1090820X13484492">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pessa</surname><given-names>JE</given-names></name>
<name><surname>Zadoo</surname><given-names>VP</given-names></name>
<name><surname>Adrian</surname><given-names>EK</given-names></name><etal/>
</person-group>. <article-title>Anatomy of a “black eye”: a newly described fascial system of the lower eyelid</article-title>. <source>Clin Anat</source>. <year>1998</year>;<volume>11</volume>:<fpage>157</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr84-1090820X13484492">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pessa</surname><given-names>JE</given-names></name>
<name><surname>Garza</surname><given-names>JR</given-names></name>
</person-group>. <article-title>The malar septum: the anatomic basis of malar mounds and malar edema</article-title>. <source>Aesthetic Surg J</source>. <year>1997</year>;<volume>17</volume>:<fpage>11</fpage>-<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr85-1090820X13484492">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funt</surname><given-names>DK</given-names></name>
</person-group>. <article-title>Avoiding malar edema during midface/cheek augmentation with dermal fillers</article-title>. <source>J Clin Aesthetic Dermatol</source>. <year>2011</year>;<volume>4</volume>:<fpage>32</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr86-1090820X13484492">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Peng</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Blending of the eyelid-cheek junction and removal of protruding fat: an intraoral approach to blepharoplasty of the lower eyelid</article-title>. <source>Br J Oral Maxillofac Surg</source>. <year>2009</year>;<volume>47</volume>:<fpage>541</fpage>-<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr87-1090820X13484492">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>SH</given-names></name>
<name><surname>Hwang</surname><given-names>K</given-names></name>
<name><surname>Jin</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Location and nature of retro-orbicularis oculus fat and suborbicularis oculi fat</article-title>. <source>J Craniofac Surg</source>. <year>2007</year>;<volume>18</volume>:<fpage>387</fpage>-<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr88-1090820X13484492">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yousif</surname><given-names>NJ</given-names></name>
<name><surname>Sonderman</surname><given-names>P</given-names></name>
<name><surname>Dzwierzynski</surname><given-names>WW</given-names></name><etal/>
</person-group>. <article-title>Anatomic considerations in transconjunctival blepharoplasty</article-title>. <source>Plast Reconstr Surg</source>. <year>1995</year>;<volume>96</volume>:<fpage>1271</fpage>-<lpage>1276</lpage>; discussion <fpage>1277</fpage>-<lpage>1278</lpage>.</citation>
</ref>
<ref id="bibr89-1090820X13484492">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ilankovan</surname><given-names>V</given-names></name>
</person-group>. <article-title>Transconjunctival approach to the infraorbital region: a cadaveric and clinical study</article-title>. <source>Br J Oral Maxillofac Surg</source>. <year>1991</year>;<volume>29</volume>:<fpage>169</fpage>-<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr90-1090820X13484492">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laurent</surname><given-names>TC</given-names></name>
<name><surname>Fraser</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Hyaluronan</article-title>. <source>Faseb J</source>. <year>1992</year>;<volume>6</volume>:<fpage>2397</fpage>-<lpage>2404</lpage>.</citation>
</ref>
<ref id="bibr91-1090820X13484492">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brandt</surname><given-names>FS</given-names></name>
<name><surname>Cazzaniga</surname><given-names>A</given-names></name>
</person-group>. <article-title>Hyaluronic acid gel fillers in the management of facial aging</article-title>. <source>Clin Interv Aging</source>. <year>2008</year>;<volume>3</volume>:<fpage>153</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr92-1090820X13484492">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douse-Dean</surname><given-names>T</given-names></name>
<name><surname>Jacob</surname><given-names>CI</given-names></name>
</person-group>. <article-title>Fast and easy treatment for reduction of the Tyndall effect secondary to cosmetic use of hyaluronic acid</article-title>. <source>J Drugs Dermatol</source>. <year>2008</year>;<volume>7</volume>:<fpage>281</fpage>-<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr93-1090820X13484492">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fezza</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Nonsurgical treatment of cicatricial ectropion with hyaluronic acid filler</article-title>. <source>Plast Reconstr Surg</source>. <year>2008</year>;<volume>121</volume>:<fpage>1009</fpage>-<lpage>1014</lpage>.</citation>
</ref>
<ref id="bibr94-1090820X13484492">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Narurkar</surname><given-names>V</given-names></name>
<name><surname>Carruthers</surname><given-names>J</given-names></name>
</person-group>. <article-title>Management of injected hyaluronic acid induced Tyndall effects</article-title>. <source>Lasers Surg Med</source>. <year>2006</year>;<volume>38</volume>:<fpage>202</fpage>-<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr95-1090820X13484492">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alijotas-Reig</surname><given-names>J</given-names></name>
<name><surname>Garcia-Gimenez</surname><given-names>V</given-names></name>
</person-group>. <article-title>Delayed immune-mediated adverse effects related to hyaluronic acid and acrylic hydrogel dermal fillers: clinical findings, long-term follow-up and review of the literature</article-title>. <source>J Eur Acad Dermatol Venereol</source>. <year>2008</year>;<volume>22</volume>:<fpage>150</fpage>-<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr96-1090820X13484492">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bachmann</surname><given-names>F</given-names></name>
<name><surname>Erdmann</surname><given-names>R</given-names></name>
<name><surname>Hartmann</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>The spectrum of adverse reactions after treatment with injectable fillers in the glabellar region: results from the Injectable Filler Safety Study</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1629</fpage>-<lpage>1634</lpage>.</citation>
</ref>
<ref id="bibr97-1090820X13484492">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bergeret-Galley</surname><given-names>C</given-names></name>
<name><surname>Latouche</surname><given-names>X</given-names></name>
<name><surname>Illouz</surname><given-names>YG</given-names></name>
</person-group>. <article-title>The value of a new filler material in corrective and cosmetic surgery: DermaLive and DermaDeep</article-title>. <source>Aesthetic Plast Surg</source>. <year>2001</year>;<volume>25</volume>:<fpage>249</fpage>-<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr98-1090820X13484492">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>M</given-names></name>
<name><surname>Braun</surname><given-names>S</given-names></name>
</person-group>. <article-title>Nodule formation following lip augmentation using porcine collagen-derived filler</article-title>. <source>J Drugs Dermatol</source>. <year>2008</year>;<volume>7</volume>:<fpage>579</fpage>-<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr99-1090820X13484492">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>L</given-names></name>
<name><surname>Breiting</surname><given-names>V</given-names></name>
<name><surname>Janssen</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions to injectable soft tissue permanent fillers</article-title>. <source>Aesthetic Plast Surg</source>. <year>2005</year>;<volume>29</volume>:<fpage>34</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr100-1090820X13484492">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Massone</surname><given-names>C</given-names></name>
<name><surname>Horn</surname><given-names>M</given-names></name>
<name><surname>Kerl</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Foreign body granuloma due to Matridex injection for cosmetic purposes</article-title>. <source>Am J Dermatopathol</source>. <year>2009</year>;<volume>31</volume>:<fpage>197</fpage>-<lpage>199</lpage>.</citation>
</ref>
<ref id="bibr101-1090820X13484492">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossner</surname><given-names>M</given-names></name>
<name><surname>Rossner</surname><given-names>F</given-names></name>
<name><surname>Bachmann</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Risk of severe adverse reactions to an injectable filler based on a fixed combination of hydroxyethylmethacrylate and ethylmethacrylate with hyaluronic acid</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>367</fpage>-<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr102-1090820X13484492">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiest</surname><given-names>LG</given-names></name>
<name><surname>Stolz</surname><given-names>W</given-names></name>
<name><surname>Schroeder</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Electron microscopic documentation of late changes in permanent fillers and clinical management of granulomas in affected patients</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1681</fpage>-<lpage>1688</lpage>.</citation>
</ref>
<ref id="bibr103-1090820X13484492">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zielke</surname><given-names>H</given-names></name>
<name><surname>Wolber</surname><given-names>L</given-names></name>
<name><surname>Wiest</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Risk profiles of different injectable fillers: results from the Injectable Filler Safety Study (IFS Study)</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>:<fpage>326</fpage>-<lpage>335</lpage>; discussion <fpage>335</fpage>.</citation>
</ref>
<ref id="bibr104-1090820X13484492">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alam</surname><given-names>M</given-names></name>
<name><surname>Yoo</surname><given-names>SS</given-names></name>
</person-group>. <article-title>Technique for calcium hydroxylapatite injection for correction of nasolabial fold depressions</article-title>. <source>J Am Acad Dermatol</source>. <year>2007</year>;<volume>56</volume>:<fpage>285</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr105-1090820X13484492">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alcalay</surname><given-names>J</given-names></name>
<name><surname>Alkalay</surname><given-names>R</given-names></name>
<name><surname>Gat</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Late-onset granulomatous reaction to Artecoll</article-title>. <source>Dermatol Surg</source>. <year>2003</year>;<volume>29</volume>:<fpage>859</fpage>-<lpage>862</lpage>.</citation>
</ref>
<ref id="bibr106-1090820X13484492">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alijotas-Reig</surname><given-names>J</given-names></name>
<name><surname>Garcia-Gimenez</surname><given-names>V</given-names></name>
<name><surname>Miro-Mur</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Delayed immune-mediated adverse effects of polyalkylimide dermal fillers: clinical findings and long-term follow-up</article-title>. <source>Arch Dermatol</source>. <year>2008</year>;<volume>144</volume>:<fpage>637</fpage>-<lpage>642</lpage>.</citation>
</ref>
<ref id="bibr107-1090820X13484492">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alijotas-Reig</surname><given-names>J</given-names></name>
<name><surname>Garcia-Gimenez</surname><given-names>V</given-names></name>
<name><surname>Miro-Mur</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Delayed immune-mediated adverse effects related to polyacrylamide dermal fillers: clinical findings, management, and follow-up</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>360</fpage>-<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr108-1090820X13484492">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alijotas-Reig</surname><given-names>J</given-names></name>
<name><surname>Garcia-Gimenez</surname><given-names>V</given-names></name>
<name><surname>Vilardell-Tarres</surname><given-names>M</given-names></name>
</person-group>. <article-title>Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up</article-title>. <source>Dermatology</source>. <year>2009</year>;<volume>219</volume>:<fpage>303</fpage>-<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr109-1090820X13484492">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amin</surname><given-names>SP</given-names></name>
<name><surname>Marmur</surname><given-names>ES</given-names></name>
<name><surname>Goldberg</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Complications from injectable polyacrylamide gel, a new nonbiodegradable soft tissue filler</article-title>. <source>Dermatol Surg</source>. <year>2004</year>;<volume>30</volume>:<fpage>1507</fpage>-<lpage>1509</lpage>.</citation>
</ref>
<ref id="bibr110-1090820X13484492">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anwar</surname><given-names>MU</given-names></name>
<name><surname>Sharpe</surname><given-names>DT</given-names></name>
</person-group>. <article-title>Skin nodules after semipermanent cosmetic dermal filler</article-title>. <source>Aesthetic Plast Surg</source>. <year>2007</year>;<volume>31</volume>: <fpage>401</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr111-1090820X13484492">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bass</surname><given-names>LS</given-names></name>
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Busso</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Calcium hydroxylapatite (Radiesse) for treatment of nasolabial folds: long-term safety and efficacy results</article-title>. <source>Aesthetic Surg J</source>. <year>2010</year>;<volume>30</volume>:<fpage>235</fpage>-<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr112-1090820X13484492">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Belmontesi</surname><given-names>M</given-names></name>
<name><surname>Grover</surname><given-names>R</given-names></name>
<name><surname>Verpaele</surname><given-names>A</given-names></name>
</person-group>. <article-title>Transdermal injection of Restylane SubQ for aesthetic contouring of the cheeks, chin, and mandible</article-title>. <source>Aesthetic Surgery J</source>. <year>2006</year>;<volume>26</volume>:<fpage>S28</fpage>-<lpage>S34</lpage>.</citation>
</ref>
<ref id="bibr113-1090820X13484492">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burgess</surname><given-names>CM</given-names></name>
<name><surname>Quiroga</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy</article-title>. <source>J Am Acad Dermatol</source>. <year>2005</year>;<volume>52</volume>:<fpage>233</fpage>-<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr114-1090820X13484492">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cosatti</surname><given-names>M</given-names></name>
<name><surname>Fernandez Romero</surname><given-names>DS</given-names></name>
<name><surname>Juri</surname><given-names>MC</given-names></name><etal/>
</person-group>. <article-title>Facial angioedema after filler injections: description of five cases [in Spanish]</article-title>. <source>Medicina</source>. <year>2010</year>;<volume>70</volume>:<fpage>513</fpage>-<lpage>517</lpage>.</citation>
</ref>
<ref id="bibr115-1090820X13484492">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heinz</surname><given-names>BC</given-names></name>
<name><surname>Ladhoff</surname><given-names>U</given-names></name>
<name><surname>Kahl</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Survey of incidents associated with injectable dermal fillers reported to the German Medical Devices Vigilance System [in German]</article-title>. <source>Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz</source>. <year>2008</year>;<volume>51</volume>:<fpage>787</fpage>-<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr116-1090820X13484492">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jansen</surname><given-names>DA</given-names></name>
<name><surname>Graivier</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Evaluation of a calcium hydroxylapatite-based implant (Radiesse) for facial soft-tissue augmentation</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>118</volume>:<fpage>22S</fpage>-<lpage>30S</lpage>, discussion <fpage>31S</fpage>-<lpage>33S</lpage>.</citation>
</ref>
<ref id="bibr117-1090820X13484492">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
<name><surname>Wolters</surname><given-names>M</given-names></name>
</person-group>. <article-title>[Complications after dermal fillers and their treatment [in German]</article-title>. <source>Handchir Mikrochir Plast Chir</source>. <year>2006</year>;<volume>38</volume>:<fpage>354</fpage>-<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr118-1090820X13484492">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moscona</surname><given-names>RA</given-names></name>
<name><surname>Fodor</surname><given-names>L</given-names></name>
</person-group>. <article-title>A retrospective study on liquid injectable silicone for lip augmentation: long-term results and patient satisfaction</article-title>. <source>J Plast Reconstr Aesthetic Surg</source>. <year>2010</year>;<volume>63</volume>:<fpage>1694</fpage>-<lpage>1698</lpage>.</citation>
</ref>
<ref id="bibr119-1090820X13484492">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Narins</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Minimizing adverse events associated with poly-L-lactic acid injection</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S100</fpage>-<lpage>S104</lpage>.</citation>
</ref>
<ref id="bibr120-1090820X13484492">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ross</surname><given-names>AH</given-names></name>
<name><surname>Malhotra</surname><given-names>R</given-names></name>
</person-group>. <article-title>Long-term orbitofacial complications of polyalkylimide 4% (bio-alcamid)</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>394</fpage>-<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr121-1090820X13484492">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossner</surname><given-names>F</given-names></name>
<name><surname>Rossner</surname><given-names>M</given-names></name>
<name><surname>Hartmann</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Decrease of reported adverse events to injectable polylactic acid after recommending an increased dilution: 8-year results from the Injectable Filler Safety study</article-title>. <source>J Cosmet Dermatol</source>. <year>2009</year>;<volume>8</volume>:<fpage>14</fpage>-<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr122-1090820X13484492">
<label>122.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sadick</surname><given-names>NS</given-names></name>
<name><surname>Katz</surname><given-names>BE</given-names></name>
<name><surname>Roy</surname><given-names>D</given-names></name>
</person-group>. <article-title>A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face</article-title>. <source>Dermatol Surg</source>. <year>2007</year>;<volume>33</volume>(<supplement>suppl 2</supplement>):<fpage>S122</fpage>-<lpage>126</lpage>; discussion <fpage>S126</fpage>-<lpage>S127</lpage>.</citation>
</ref>
<ref id="bibr123-1090820X13484492">
<label>123.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartzfarb</surname><given-names>EM</given-names></name>
<name><surname>Hametti</surname><given-names>JM</given-names></name>
<name><surname>Romanelli</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Foreign body granuloma formation secondary to silicone injection</article-title>. <source>Dermatol Online J</source>. <year>2008</year>;<volume>14</volume>:<fpage>20</fpage>.</citation>
</ref>
<ref id="bibr124-1090820X13484492">
<label>124.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thyssen</surname><given-names>JP</given-names></name>
<name><surname>Christensen</surname><given-names>LH</given-names></name>
<name><surname>Zachariae</surname><given-names>CO</given-names></name>
</person-group>. <article-title>Cosmetic soft-tissue augmentation treatment [in Danish]</article-title>. <source>Ugesk Laeger</source>. <year>2007</year>;<volume>169</volume>:<fpage>2198</fpage>-<lpage>2201</lpage>.</citation>
</ref>
<ref id="bibr125-1090820X13484492">
<label>125.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tzikas</surname><given-names>TL</given-names></name>
</person-group>. <article-title>Evaluation of the Radiance FN soft tissue filler for facial soft tissue augmentation</article-title>. <source>Arch Facial Plast Surg</source>. <year>2004</year>;<volume>6</volume>:<fpage>234</fpage>-<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr126-1090820X13484492">
<label>126.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>YB</given-names></name>
<name><surname>Huang</surname><given-names>JJ</given-names></name>
<name><surname>Qiao</surname><given-names>Q</given-names></name><etal/>
</person-group>. <article-title>Clinically analyzing the possible side-effects after injecting hydrophilic polyacrylamide gel as a soft-tissue filler in Chinese]</article-title>. <source>Zhonghua Zheng Xing Wai Ke Za Zhi</source>. <year>2003</year>;<volume>19</volume>:<fpage>328</fpage>-<lpage>330</lpage>.</citation>
</ref>
<ref id="bibr127-1090820X13484492">
<label>127.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiest</surname><given-names>LG</given-names></name>
</person-group>. <article-title>History and use of fillers for treating wrinkles [in German]</article-title>. <source>Hautarzt</source>. <year>2007</year>;<volume>58</volume>:<fpage>224</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr128-1090820X13484492">
<label>128.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cassuto</surname><given-names>D</given-names></name>
<name><surname>Marangoni</surname><given-names>O</given-names></name>
<name><surname>De Santis</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Advanced laser techniques for filler-induced complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1689</fpage>-<lpage>1695</lpage>.</citation>
</ref>
<ref id="bibr129-1090820X13484492">
<label>129.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cohen</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Understanding, avoiding, and managing dermal filler complications</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S92</fpage>-<lpage>S99</lpage>.</citation>
</ref>
<ref id="bibr130-1090820X13484492">
<label>130.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laube</surname><given-names>S</given-names></name>
</person-group>. <article-title>Skin infections and ageing</article-title>. <source>Ageing Res Rev</source>. <year>2004</year>;<volume>3</volume>:<fpage>69</fpage>-<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr131-1090820X13484492">
<label>131.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diaz</surname><given-names>LA</given-names></name>
<name><surname>Giudice</surname><given-names>GJ</given-names></name>
</person-group>. <article-title>End of the century overview of skin blisters</article-title>. <source>Arch Dermatol</source>. <year>2000</year>;<volume>136</volume>:<fpage>106</fpage>-<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr132-1090820X13484492">
<label>132.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oranje</surname><given-names>AP</given-names></name>
<name><surname>Folkers</surname><given-names>E</given-names></name>
<name><surname>Choufoer-Habova</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Diagnostic value of Tzanck smear in herpetic and non-herpetic vesicular and bullous skin disorders in pediatric practice</article-title>. <source>Acta Derm Venereol</source>. <year>1986</year>;<volume>66</volume>:<fpage>127</fpage>-<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr133-1090820X13484492">
<label>133.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klastersky</surname><given-names>J</given-names></name>
</person-group>. <article-title>Infections in immunocompromised patients, I: pathogenesis, etiology, and diagnosis</article-title>. <source>Clin Ther</source>. <year>1985</year>;<volume>8</volume>:<fpage>90</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr134-1090820X13484492">
<label>134.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sadashivaiah</surname><given-names>AB</given-names></name>
<name><surname>Mysore</surname><given-names>V</given-names></name>
</person-group>. <article-title>Biofilms: their role in dermal fillers</article-title>. <source>J Cutan Aesthetic Surg</source>. <year>2010</year>;<volume>3</volume>:<fpage>20</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr135-1090820X13484492">
<label>135.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Bacterial biofilms and human disease</article-title>. <source>Sci Progress</source>. <year>2001</year>;<volume>84</volume>:<fpage>235</fpage>-<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr136-1090820X13484492">
<label>136.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costerton</surname><given-names>JW</given-names></name>
<name><surname>Montanaro</surname><given-names>L</given-names></name>
<name><surname>Arciola</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Biofilm in implant infections: its production and regulation</article-title>. <source>Int J Artif Organs</source>. <year>2005</year>;<volume>28</volume>:<fpage>1062</fpage>-<lpage>1068</lpage>.</citation>
</ref>
<ref id="bibr137-1090820X13484492">
<label>137.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wadstrom</surname><given-names>T</given-names></name>
</person-group>. <article-title>Molecular aspects of bacterial adhesion, colonization, and development of infections associated with biomaterials</article-title>. <source>J Invest Surg</source>. <year>1989</year>;<volume>2</volume>:<fpage>353</fpage>-<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr138-1090820X13484492">
<label>138.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramage</surname><given-names>G</given-names></name>
<name><surname>Culshaw</surname><given-names>S</given-names></name>
<name><surname>Jones</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Are we any closer to beating the biofilm: novel methods of biofilm control</article-title>. <source>Curr Opin Infect Dis</source>. <year>2010</year>;<volume>23</volume>:<fpage>560</fpage>-<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr139-1090820X13484492">
<label>139.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCann</surname><given-names>MT</given-names></name>
<name><surname>Gilmore</surname><given-names>BF</given-names></name>
<name><surname>Gorman</surname><given-names>SP</given-names></name>
</person-group>. <article-title><italic>Staphylococcus epidermidis</italic> device-related infections: pathogenesis and clinical management</article-title>. <source>J Pharm Pharmacol</source>. <year>2008</year>;<volume>60</volume>: <fpage>1551</fpage>-<lpage>1571</lpage>.</citation>
</ref>
<ref id="bibr140-1090820X13484492">
<label>140.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uckay</surname><given-names>I</given-names></name>
<name><surname>Pittet</surname><given-names>D</given-names></name>
<name><surname>Vaudaux</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Foreign body infections due to <italic>Staphylococcus epidermidis</italic></article-title>. <source>Ann Med</source>. <year>2009</year>;<volume>41</volume>:<fpage>109</fpage>-<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr141-1090820X13484492">
<label>141.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miclau</surname><given-names>T</given-names></name>
<name><surname>Schmidt</surname><given-names>AH</given-names></name>
<name><surname>Wenke</surname><given-names>JC</given-names></name><etal/>
</person-group>. <article-title>Infection</article-title>. <source>J Orthop Trauma</source>. <year>2010</year>;<volume>24</volume>:<fpage>583</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr142-1090820X13484492">
<label>142.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>C</given-names></name>
<name><surname>Thys</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Prosthesis-related infections [in French]</article-title>. <source>Rev Med Brux</source>. <year>2000</year>;<volume>21</volume>:<fpage>143</fpage>-<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr143-1090820X13484492">
<label>143.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>El-Shafey el</surname><given-names>SI</given-names></name>
</person-group>. <article-title>Complications from repeated injection or puncture of old polyacrylamide gel implant sites: case reports</article-title>. <source>Aesthetic Plast Surg</source>. <year>2008</year>;<volume>32</volume>:<fpage>162</fpage>-<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr144-1090820X13484492">
<label>144.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallo</surname><given-names>J</given-names></name>
<name><surname>Kolar</surname><given-names>M</given-names></name>
<name><surname>Novotny</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Pathogenesis of prosthesis-related infection</article-title>. <source>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</source>. <year>2003</year>;<volume>147</volume>:<fpage>27</fpage>-<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr145-1090820X13484492">
<label>145.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Costerton</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Biofilm theory can guide the treatment of device-related orthopaedic infections</article-title>. <source>Clin Orthop Relat Res</source>. <year>2005</year>;(<issue>437</issue>):<fpage>7</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr146-1090820X13484492">
<label>146.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winkler</surname><given-names>H</given-names></name>
</person-group>. <article-title>Rationale for one stage exchange of infected hip replacement using uncemented implants and antibiotic impregnated bone graft</article-title>. <source>Int J Med Sci</source>. <year>2009</year>;<volume>6</volume>:<fpage>247</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr147-1090820X13484492">
<label>147.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marusza</surname><given-names>W</given-names></name>
<name><surname>Mlynarczyk</surname><given-names>G</given-names></name>
<name><surname>Olszanski</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Probable biofilm formation in the cheek as a complication of soft tissue filler resulting from improper endodontic treatment of tooth 16</article-title>. <source>Int J Nanomed</source>. <year>2012</year>;<volume>7</volume>:<fpage>1441</fpage>-<lpage>1447</lpage>.</citation>
</ref>
<ref id="bibr148-1090820X13484492">
<label>148.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dayan</surname><given-names>SH</given-names></name>
<name><surname>Arkins</surname><given-names>JP</given-names></name>
<name><surname>Brindise</surname><given-names>R</given-names></name>
</person-group>. <article-title>Soft tissue fillers and biofilms</article-title>. <source>Facial Plast Surg</source>. <year>2011</year>;<volume>27</volume>:<fpage>23</fpage>-<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr149-1090820X13484492">
<label>149.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassid</surname><given-names>VJ</given-names></name>
</person-group>. <article-title>Soft-tissue filler complications: the important role of biofilms</article-title>. <source>Plast Reconstr Surg</source>. <year>2010</year>;<volume>126</volume>:<fpage>1801</fpage>-<lpage>1802</lpage>; author reply <fpage>1802</fpage>.</citation>
</ref>
<ref id="bibr150-1090820X13484492">
<label>150.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crosby</surname><given-names>CT</given-names></name>
<name><surname>Tsj</surname><given-names>E</given-names></name>
<name><surname>Lambert</surname><given-names>PA</given-names></name><etal/>
</person-group>. <article-title>Preoperative skin preparation: a historical perspective</article-title>. <source>Br J Hosp Med (Lond)</source>. <year>2009</year>;<volume>70</volume>:<fpage>579</fpage>-<lpage>582</lpage>.</citation>
</ref>
<ref id="bibr151-1090820X13484492">
<label>151.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yokoe</surname><given-names>DS</given-names></name>
<name><surname>Mermel</surname><given-names>LA</given-names></name>
<name><surname>Anderson</surname><given-names>DJ</given-names></name><etal/>
</person-group>. <article-title>A compendium of strategies to prevent healthcare-associated infections in acute care hospitals</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>2008</year>;<volume>29</volume>(<supplement>suppl 1</supplement>):<fpage>S12</fpage>-<lpage>S21</lpage>.</citation>
</ref>
<ref id="bibr152-1090820X13484492">
<label>152.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pratt</surname><given-names>RJ</given-names></name>
<name><surname>O’Malley</surname><given-names>B</given-names></name>
</person-group>. <article-title>Supporting evidence-based infection prevention and control practice in the National Health Service in England. The NHS/TVU/Intuition Approach</article-title>. <source>J Hosp Infect</source>. <year>2007</year>;<volume>65</volume>(<supplement>suppl 2</supplement>):<fpage>142</fpage>-<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr153-1090820X13484492">
<label>153.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pratt</surname><given-names>RJ</given-names></name>
<name><surname>Pellowe</surname><given-names>CM</given-names></name>
<name><surname>Wilson</surname><given-names>JA</given-names></name><etal/>
</person-group>. <article-title>epic2: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England</article-title>. <source>J Hosp Infect</source>. <year>2007</year>;<volume>65</volume>(<supplement>suppl 1</supplement>):<fpage>S1</fpage>-<lpage>S64</lpage>.</citation>
</ref>
<ref id="bibr154-1090820X13484492">
<label>154.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inwood</surname><given-names>S</given-names></name>
</person-group>. <article-title>Skin antisepsis: using 2% chlorhexidine gluconate in 70% isopropyl alcohol</article-title>. <source>Br J Nurs</source>. <year>2007</year>;<volume>16</volume>:<volume>1390</volume>, <fpage>1392</fpage>-<lpage>1394</lpage>.</citation>
</ref>
<ref id="bibr155-1090820X13484492">
<label>155.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caldellas</surname><given-names>AV</given-names></name>
<name><surname>de Castro</surname><given-names>CC</given-names></name>
<name><surname>Aboudib</surname><given-names>JH</given-names></name><etal/>
</person-group>. <article-title>The polymethylmethacrylate effects on auricle conchal cartilage: report of 21 cases</article-title>. <source>Aesthetic Surg J</source>. <year>2010</year>;<volume>30</volume>:<fpage>434</fpage>-<lpage>438</lpage>.</citation>
</ref>
<ref id="bibr156-1090820X13484492">
<label>156.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>J</given-names></name>
<name><surname>Metzler</surname><given-names>G</given-names></name>
<name><surname>Schaller</surname><given-names>M</given-names></name>
</person-group>. <article-title>Cosmetic permanent fillers for soft tissue augmentation: a new contraindication for interferon therapies</article-title>. <source>Arch Dermatol</source>. <year>2007</year>;<volume>143</volume>: <fpage>507</fpage>-<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr157-1090820X13484492">
<label>157.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Judodihardjo</surname><given-names>H</given-names></name>
<name><surname>Dykes</surname><given-names>P</given-names></name>
</person-group>. <article-title>Objective and subjective measurements of cutaneous inflammation after a novel hyaluronic acid injection</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<supplement>suppl 1</supplement>):<fpage>S110</fpage>-<lpage>S114</lpage>.</citation>
</ref>
<ref id="bibr158-1090820X13484492">
<label>158.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Winslow</surname><given-names>CP</given-names></name>
</person-group>. <article-title>The management of dermal filler complications</article-title>. <source>Facial Plast Surg</source>. <year>2009</year>;<volume>25</volume>:<fpage>124</fpage>-<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr159-1090820X13484492">
<label>159.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Childs</surname><given-names>D.</given-names></name>
</person-group> <article-title>Boosting butts with cement, Fix-A-Flat, leads to arrest</article-title>. <ext-link ext-link-type="uri" xlink:href="http://abcnews.go.com/blogs/health/2011/11/18/man-arrested-for-boosting-butts-with-cement-fix-a-flat/">http://abcnews.go.com/blogs/health/2011/11/18/man-arrested-for-boosting-butts-with-cement-fix-a-flat/</ext-link>. <access-date>Accessed March 25, 2013</access-date>.</citation>
</ref>
<ref id="bibr160-1090820X13484492">
<label>160.</label>
<citation citation-type="web">
<article-title>Crimesider staff alleged “Fix-a-Flat” fake surgeon Oneal Ron Morris arrested again after more victims come forward</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.cbsnews.com/8301-504083_162-57397200-504083/alleged-fix-a-flat-fake-surgeon-oneal-ron-morris-arrested-again-after-more-victims-come-forward/">http://www.cbsnews.com/8301-504083_162-57397200-504083/alleged-fix-a-flat-fake-surgeon-oneal-ron-morris-arrested-again-after-more-victims-come-forward/</ext-link>. <access-date>Accessed March 25, 2013</access-date></citation>
</ref>
<ref id="bibr161-1090820X13484492">
<label>161.</label>
<citation citation-type="web">
<collab>Florida Department of Health Press Release</collab>. <article-title>Florida Department of Health’s joint efforts result in felony arrest-partnered investigation highlights department’s unlicensed activity unit</article-title>, <month>July</month> <day>27</day>, <year>2012</year>. <ext-link ext-link-type="uri" xlink:href="http://newsroom.doh.state.fl.us/wp-content/uploads/newsroom/2011/08/72712Brwrd.pdf">http://newsroom.doh.state.fl.us/wp-content/uploads/newsroom/2011/08/72712Brwrd.pdf</ext-link>. <access-date>Accessed March 25, 2013</access-date></citation>
</ref>
<ref id="bibr162-1090820X13484492">
<label>162.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sachdev</surname><given-names>M</given-names></name>
<name><surname>Anantheswar</surname><given-names>Y</given-names></name>
<name><surname>Ashok</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Facial granulomas secondary to injection of semi-permanent cosmetic dermal filler containing acrylic hydrogel particles</article-title>. <source>J Cutan Aesthetic Surg</source>. <year>2010</year>;<volume>3</volume>:<fpage>162</fpage>-<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr163-1090820X13484492">
<label>163.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Planas</surname><given-names>J</given-names></name>
</person-group>. <article-title>The use of Integra in rhinoplasty</article-title>. <source>Aesthetic Plast Surg</source>. <year>2010</year>;<volume>35</volume>:<fpage>5</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr164-1090820X13484492">
<label>164.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manafi</surname><given-names>A</given-names></name>
<name><surname>Emami</surname><given-names>AH</given-names></name>
<name><surname>Pooli</surname><given-names>AH</given-names></name><etal/>
</person-group>. <article-title>Unacceptable results with an accepted soft tissue filler: polyacrylamide hydrogel</article-title>. <source>Aesthetic Plast Surg</source>. <year>2010</year>;<volume>34</volume>:<fpage>413</fpage>-<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr165-1090820X13484492">
<label>165.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sneistrup</surname><given-names>C</given-names></name>
<name><surname>Holmich</surname><given-names>LR</given-names></name>
<name><surname>Dahlstrom</surname><given-names>K</given-names></name>
</person-group>. <article-title>Long-term complications after injection of permanent tissue-fillers to the lips [in Danish]</article-title>. <source>Ugeskr Laeger</source>. <year>2009</year>;<volume>171</volume>:<year>1414</year>.</citation>
</ref>
<ref id="bibr166-1090820X13484492">
<label>166.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shaeer</surname><given-names>O</given-names></name>
<name><surname>Shaeer</surname><given-names>K</given-names></name>
</person-group>. <article-title>Delayed complications of gel injection for penile girth augmentation</article-title>. <source>J Sex Med</source>. <year>2009</year>;<volume>6</volume>:<fpage>2072</fpage>-<lpage>2078</lpage>.</citation>
</ref>
<ref id="bibr167-1090820X13484492">
<label>167.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sclafani</surname><given-names>AP</given-names></name>
<name><surname>Fagien</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of injectable soft tissue filler complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1672</fpage>-<lpage>1680</lpage>.</citation>
</ref>
<ref id="bibr168-1090820X13484492">
<label>168.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schelke</surname><given-names>LW</given-names></name>
<name><surname>van den Elzen</surname><given-names>HJ</given-names></name>
<name><surname>Canninga</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Complications after treatment with polyalkylimide</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1625</fpage>-<lpage>1628</lpage>.</citation>
</ref>
<ref id="bibr169-1090820X13484492">
<label>169.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sanchis-Bielsa</surname><given-names>JM</given-names></name>
<name><surname>Bagan</surname><given-names>JV</given-names></name>
<name><surname>Poveda</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Foreign body granulomatous reactions to cosmetic fillers: a clinical study of 15 cases</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2009</year>;<volume>108</volume>:<fpage>237</fpage>-<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr170-1090820X13484492">
<label>170.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sage</surname><given-names>RJ</given-names></name>
<name><surname>Chaffins</surname><given-names>ML</given-names></name>
<name><surname>Kouba</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Granulomatous foreign body reaction to hyaluronic acid: report of a case after melolabial fold augmentation and review of management</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1696</fpage>-<lpage>1700</lpage>.</citation>
</ref>
<ref id="bibr171-1090820X13484492">
<label>171.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reszko</surname><given-names>AE</given-names></name>
<name><surname>Sadick</surname><given-names>NS</given-names></name>
<name><surname>Magro</surname><given-names>CM</given-names></name><etal/>
</person-group>. <article-title>Late-onset subcutaneous nodules after poly-L-lactic acid injection</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>380</fpage>-<lpage>384</lpage>.</citation>
</ref>
<ref id="bibr172-1090820X13484492">
<label>172.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Guiraud</surname><given-names>A</given-names></name>
</person-group>. <article-title>Adverse reactions to injectable fillers [in French]</article-title>. <source>Ann Dermatol Venereol</source>. <year>2009</year>;<volume>136</volume>(<supplement>suppl 6</supplement>):<fpage>S293</fpage>-<lpage>S298</lpage>.</citation>
</ref>
<ref id="bibr173-1090820X13484492">
<label>173.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Monheit</surname><given-names>GD</given-names></name>
<name><surname>Rohrich</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>The nature of long-term fillers and the risk of complications</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1598</fpage>-<lpage>1604</lpage>.</citation>
</ref>
<ref id="bibr174-1090820X13484492">
<label>174.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manafi</surname><given-names>A</given-names></name>
<name><surname>Emami</surname><given-names>AH</given-names></name>
<name><surname>Pooli</surname><given-names>AH</given-names></name><etal/>
</person-group>. <article-title>Unacceptable results with an accepted soft tissue filler: polyacrylamide hydrogel</article-title>. <source>Aesthetic Plast Surg</source>. <year>2010</year>;<volume>34</volume>:<fpage>413</fpage>-<lpage>422</lpage></citation>
</ref>
<ref id="bibr175-1090820X13484492">
<label>175.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mamelak</surname><given-names>AJ</given-names></name>
<name><surname>Katz</surname><given-names>TM</given-names></name>
<name><surname>Goldberg</surname><given-names>LH</given-names></name><etal/>
</person-group>. <article-title>Foreign body reaction to hyaluronic acid filler injection: in search of an etiology</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 2</supplement>):<fpage>1701</fpage>-<lpage>1703</lpage>.</citation>
</ref>
<ref id="bibr176-1090820X13484492">
<label>176.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Sadick</surname><given-names>NS</given-names></name>
<name><surname>Knapp</surname><given-names>TR</given-names></name><etal/>
</person-group>. <article-title>ArteFill permanent injectable for soft tissue augmentation, II: indications and applications</article-title>. <source>Aesthetic Plast Surg</source>. <year>2010</year>;<volume>34</volume>:<fpage>273</fpage>-<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr177-1090820X13484492">
<label>177.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Gauthier-Hazan</surname><given-names>N</given-names></name>
<name><surname>Wolters</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Foreign body granulomas after all injectable dermal fillers, part 1: possible causes</article-title>. <source>Plast Reconstr Surg</source>. <year>2009</year>;<volume>123</volume>:<fpage>1842</fpage>-<lpage>1863</lpage>.</citation>
</ref>
<ref id="bibr178-1090820X13484492">
<label>178.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humphrey</surname><given-names>CD</given-names></name>
<name><surname>Arkins</surname><given-names>JP</given-names></name>
<name><surname>Dayan</surname><given-names>SH</given-names></name>
</person-group>. <article-title>Soft tissue fillers in the nose</article-title>. <source>Aesthetic Surg J</source>. <year>2009</year>;<volume>29</volume>:<fpage>477</fpage>-<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr179-1090820X13484492">
<label>179.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furmanczyk</surname><given-names>PS</given-names></name>
<name><surname>Wolgamot</surname><given-names>GM</given-names></name>
<name><surname>Argenyi</surname><given-names>ZB</given-names></name><etal/>
</person-group>. <article-title>Extensive granulomatous reaction occurring 1.5 years after DermaLive injection</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>385</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr180-1090820X13484492">
<label>180.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>da Costa Miguel</surname><given-names>MC</given-names></name>
<name><surname>Nonaka</surname><given-names>CF</given-names></name>
<name><surname>dos Santos</surname><given-names>JN</given-names></name><etal/>
</person-group>. <article-title>Oral foreign body granuloma: unusual presentation of a rare adverse reaction to permanent injectable cosmetic filler</article-title>. <source>Int J Oral Maxillofac Surg</source>. <year>2009</year>;<volume>38</volume>:<fpage>385</fpage>-<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr181-1090820X13484492">
<label>181.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beer</surname><given-names>K</given-names></name>
</person-group>. <article-title>Clinicopathologic correlation of delayed-onset periorbital poly-L-lactic acid nodules</article-title>. <source>Dermatol Surg</source>. <year>2009</year>;<volume>35</volume>(<supplement>suppl 1</supplement>):<fpage>399</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr182-1090820X13484492">
<label>182.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beer</surname><given-names>K</given-names></name>
</person-group>. <article-title>Delayed onset nodules from liquid injectable silicone: report of a case, evaluation of associated histopathology and results of treatment with minocycline and celocoxib</article-title>. <source>J Drugs Dermatol</source>. <year>2009</year>;<volume>8</volume>:<fpage>952</fpage>-<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr183-1090820X13484492">
<label>183.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Altmeyer</surname><given-names>MD</given-names></name>
<name><surname>Anderson</surname><given-names>LL</given-names></name>
<name><surname>Wang</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Silicone migration and granuloma formation</article-title>. <source>J Cosmet Dermatol</source>. <year>2009</year>;<volume>8</volume>: <fpage>92</fpage>-<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr184-1090820X13484492">
<label>184.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thioly-Bensoussan</surname><given-names>D</given-names></name>
</person-group>. <article-title>Non-hyaluronic acid fillers</article-title>. <source>Clin Dermatol</source>. <year>2008</year>;<volume>26</volume>:<fpage>160</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr185-1090820X13484492">
<label>185.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salles</surname><given-names>AG</given-names></name>
<name><surname>Lotierzo</surname><given-names>PH</given-names></name>
<name><surname>Gemperli</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Complications after polymethylmethacrylate injections: report of 32 cases</article-title>. <source>Plast Reconstr Surg</source>. <year>2008</year>;<volume>121</volume>:<fpage>1811</fpage>-<lpage>1820</lpage>.</citation>
</ref>
<ref id="bibr186-1090820X13484492">
<label>186.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rongioletti</surname><given-names>F</given-names></name>
</person-group>. <article-title>Granulomatous reactions from aesthetic dermal micro-implants [in French]</article-title>. <source>Ann Dermatol Venereol</source>. <year>2008</year>;<volume>135</volume>:<fpage>1S59</fpage>-<lpage>1S65</lpage>.</citation>
</ref>
<ref id="bibr187-1090820X13484492">
<label>187.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pons-Guiraud</surname><given-names>A</given-names></name>
</person-group>. <article-title>Adverse reactions to injectable fillers [in French]</article-title>. <source>Ann Dermatol Venereol</source>. <year>2008</year>;<volume>135</volume>(<supplement>suppl 3</supplement>):<fpage>S171</fpage>-<lpage>S174</lpage>.</citation>
</ref>
<ref id="bibr188-1090820X13484492">
<label>188.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>RJ</given-names></name>
<name><surname>Stier</surname><given-names>M</given-names></name>
</person-group>. <article-title>Complications of soft tissue augmentation</article-title>. <source>J Drugs Dermatol</source>. <year>2008</year>;<volume>7</volume>:<fpage>841</fpage>-<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr189-1090820X13484492">
<label>189.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonzalez-Vela</surname><given-names>MC</given-names></name>
<name><surname>Armesto</surname><given-names>S</given-names></name>
<name><surname>Gonzalez-Lopez</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Perioral granulomatous reaction to Dermalive</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>:<fpage>986</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr190-1090820X13484492">
<label>190.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fitzgerald</surname><given-names>R</given-names></name>
<name><surname>Vleggaar</surname><given-names>D</given-names></name>
<name><surname>Burgess</surname><given-names>C</given-names></name>
</person-group>. <article-title>Facial dermal fillers</article-title>. <source>Aesthetic Surg J</source>. <year>2008</year>;<volume>28</volume>:<fpage>699</fpage>-<lpage>701</lpage>; author reply <fpage>701</fpage>.</citation>
</ref>
<ref id="bibr191-1090820X13484492">
<label>191.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dayan</surname><given-names>SH</given-names></name>
<name><surname>Bassichis</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Facial dermal fillers: selection of appropriate products and techniques</article-title>. <source>Aesthetic Surg J</source>. <year>2008</year>;<volume>28</volume>:<fpage>335</fpage>-<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr192-1090820X13484492">
<label>192.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anastassov</surname><given-names>GE</given-names></name>
<name><surname>Schulhof</surname><given-names>S</given-names></name>
<name><surname>Lumerman</surname><given-names>H</given-names></name>
</person-group>. <article-title>Complications after facial contour augmentation with injectable silicone: diagnosis and treatment. Report of a severe case</article-title>. <source>Int J Oral Maxillofac Surg</source>. <year>2008</year>;<volume>37</volume>:<fpage>955</fpage>-<lpage>960</lpage>.</citation>
</ref>
<ref id="bibr193-1090820X13484492">
<label>193.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mustacchio</surname><given-names>V</given-names></name>
<name><surname>Cabibi</surname><given-names>D</given-names></name>
<name><surname>Minervini</surname><given-names>MI</given-names></name><etal/>
</person-group>. <article-title>A diagnostic trap for the dermatopathologist: granulomatous reactions from cutaneous microimplants for cosmetic purposes</article-title>. <source>J Cutan Pathol</source>. <year>2007</year>;<volume>34</volume>:<fpage>281</fpage>-<lpage>283</lpage>.</citation>
</ref>
<ref id="bibr194-1090820X13484492">
<label>194.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>PC</given-names></name>
<name><surname>Fantasia</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Review of long-term adverse effects associated with the use of chemically-modified animal and nonanimal source hyaluronic acid dermal fillers</article-title>. <source>Clin Interv Aging</source>. <year>2007</year>;<volume>2</volume>:<fpage>509</fpage>-<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr195-1090820X13484492">
<label>195.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chasan</surname><given-names>PE</given-names></name>
</person-group>. <article-title>The history of injectable silicone fluids for soft-tissue augmentation</article-title>. <source>Plast Reconstr Surg</source>. <year>2007</year>;<volume>120</volume>:<fpage>2034</fpage>-<lpage>2040</lpage>; discussion <fpage>2041</fpage>-<lpage>2043</lpage>.</citation>
</ref>
<ref id="bibr196-1090820X13484492">
<label>196.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bardazzi</surname><given-names>F</given-names></name>
<name><surname>Ruffato</surname><given-names>A</given-names></name>
<name><surname>Antonucci</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Cutaneous granulomatous reaction to injectable hyaluronic acid gel: another case</article-title>. <source>J Dermatol Treat</source>. <year>2007</year>;<volume>18</volume>:<fpage>59</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr197-1090820X13484492">
<label>197.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baijens</surname><given-names>L</given-names></name>
<name><surname>Speyer</surname><given-names>R</given-names></name>
<name><surname>Linssen</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Rejection of injectable silicone “Bioplastique” used for vocal fold augmentation</article-title>. <source>Eur Arch Otorhinolaryngol</source>. <year>2007</year>;<volume>264</volume>:<fpage>565</fpage>-<lpage>568</lpage>.</citation>
</ref>
<ref id="bibr198-1090820X13484492">
<label>198.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Shraim</surname><given-names>M</given-names></name>
<name><surname>Jaragh</surname><given-names>M</given-names></name>
<name><surname>Geddie</surname><given-names>W</given-names></name>
</person-group>. <article-title>Granulomatous reaction to injectable hyaluronic acid (Restylane) diagnosed by fine needle biopsy</article-title>. <source>J Clin Pathol</source>. <year>2007</year>;<volume>60</volume>: <fpage>1060</fpage>-<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr199-1090820X13484492">
<label>199.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wolfram</surname><given-names>D</given-names></name>
<name><surname>Tzankov</surname><given-names>A</given-names></name>
<name><surname>Piza-Katzer</surname><given-names>H</given-names></name>
</person-group>. <article-title>Surgery for foreign body reactions due to injectable fillers</article-title>. <source>Dermatology</source>. <year>2006</year>;<volume>213</volume>:<fpage>300</fpage>-<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr200-1090820X13484492">
<label>200.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vargas-Machuca</surname><given-names>I</given-names></name>
<name><surname>Gonzalez-Guerra</surname><given-names>E</given-names></name>
<name><surname>Angulo</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Facial granulomas secondary to Dermalive microimplants: report of a case with histopathologic differential diagnosis among the granulomas secondary to different injectable permanent filler materials</article-title>. <source>Am J Dermatopathol</source>. <year>2006</year>;<volume>28</volume>:<fpage>173</fpage>-<lpage>177</lpage>.</citation>
</ref>
<ref id="bibr201-1090820X13484492">
<label>201.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sidwell</surname><given-names>RU</given-names></name>
<name><surname>McL Johnson</surname><given-names>N</given-names></name>
<name><surname>Francis</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Cutaneous sarcoidal granulomas developing after Artecoll facial cosmetic filler in a patient with newly diagnosed systemic sarcoidosis</article-title>. <source>Clin Exp Dermatol</source>. <year>2006</year>;<volume>31</volume>:<fpage>208</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr202-1090820X13484492">
<label>202.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poveda</surname><given-names>R</given-names></name>
<name><surname>Bagan</surname><given-names>JV</given-names></name>
<name><surname>Murillo</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Granulomatous facial reaction to injected cosmetic fillers—a presentation of five cases [in English, Spanish]</article-title>. <source>Med Oral Patol Oral Cir Bucal</source>. <year>2006</year>;<volume>11</volume>:<fpage>E1</fpage>-<lpage>E5</lpage>.</citation>
</ref>
<ref id="bibr203-1090820X13484492">
<label>203.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>de Fazio</surname><given-names>S</given-names></name>
<name><surname>Nicolau</surname><given-names>P</given-names></name>
</person-group>. <article-title>ArteFill: a third- generation permanent dermal filler and tissue stimulator</article-title>. <source>Clin Plast Surg</source>. <year>2006</year>;<volume>33</volume>:<fpage>551</fpage>-<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr204-1090820X13484492">
<label>204.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kopera</surname><given-names>D</given-names></name>
</person-group>. <article-title>Permanent filler augmentation: common complications</article-title>. <source>Arch Dermatol</source>. <year>2006</year>;<volume>142</volume>:<year>1508</year>.</citation>
</ref>
<ref id="bibr205-1090820X13484492">
<label>205.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghislanzoni</surname><given-names>M</given-names></name>
<name><surname>Bianchi</surname><given-names>F</given-names></name>
<name><surname>Barbareschi</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Cutaneous granulomatous reaction to injectable hyaluronic acid gel</article-title>. <source>Br J Dermatol</source>. <year>2006</year>;<volume>154</volume>:<fpage>755</fpage>-<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr206-1090820X13484492">
<label>206.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>PC</given-names></name>
<name><surname>Fantasia</surname><given-names>JE</given-names></name>
<name><surname>Iovino</surname><given-names>R</given-names></name>
</person-group>. <article-title>Foreign body reaction to hyaluronic acid (Restylane): an adverse outcome of lip augmentation</article-title>. <source>J Oral Maxillofac Surg</source>. <year>2006</year>;<volume>64</volume>:<fpage>1296</fpage>-<lpage>1299</lpage>; discussion <year>1299</year>.</citation>
</ref>
<ref id="bibr207-1090820X13484492">
<label>207.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coleman</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Cross-linked hyaluronic acid fillers</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>117</volume>:<fpage>661</fpage>-<lpage>665</lpage>.</citation>
</ref>
<ref id="bibr208-1090820X13484492">
<label>208.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>U</given-names></name>
<name><surname>Vleggaar</surname><given-names>D</given-names></name>
</person-group>. <article-title>Response to “New-fill injections may induce late-onset foreign body granulomatous reaction.”</article-title> <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>118</volume>:<fpage>265</fpage>; author reply <fpage>265</fpage>-<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr209-1090820X13484492">
<label>209.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Angus</surname><given-names>JE</given-names></name>
<name><surname>Affleck</surname><given-names>AG</given-names></name>
<name><surname>Leach</surname><given-names>IH</given-names></name><etal/>
</person-group>. <article-title>Two cases of delayed granulomatous reactions to the cosmetic filler Dermalive, a hyaluronic acid and acrylic hydrogel</article-title>. <source>Br J Dermatol</source>. <year>2006</year>;<volume>155</volume>:<fpage>1077</fpage>-<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr210-1090820X13484492">
<label>210.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soparkar</surname><given-names>CN</given-names></name>
<name><surname>Patrinely</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Managing inflammatory reaction to restylane</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2005</year>;<volume>21</volume>: <fpage>151</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr211-1090820X13484492">
<label>211.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinheiro</surname><given-names>MV</given-names></name>
<name><surname>Bagatin</surname><given-names>E</given-names></name>
<name><surname>Hassun</surname><given-names>KM</given-names></name><etal/>
</person-group>. <article-title>Adverse effect of soft tissue augmentation with hyaluronic acid</article-title>. <source>J Cosmet Dermatol</source>. <year>2005</year>;<volume>4</volume>:<fpage>184</fpage>-<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr212-1090820X13484492">
<label>212.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parada</surname><given-names>MB</given-names></name>
<name><surname>Michalany</surname><given-names>NS</given-names></name>
<name><surname>Hassun</surname><given-names>KM</given-names></name><etal/>
</person-group>. <article-title>A histologic study of adverse effects of different cosmetic skin fillers</article-title>. <source>Skinmed</source>. <year>2005</year>;<volume>4</volume>:<fpage>345</fpage>-<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr213-1090820X13484492">
<label>213.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lloret</surname><given-names>P</given-names></name>
<name><surname>Espana</surname><given-names>A</given-names></name>
<name><surname>Leache</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Successful treatment of granulomatous reactions secondary to injection of esthetic implants</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>486</fpage>-<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr214-1090820X13484492">
<label>214.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fulton</surname><given-names>JE</given-names><suffix>Jr</suffix></name>
<name><surname>Porumb</surname><given-names>S</given-names></name>
<name><surname>Caruso</surname><given-names>JC</given-names></name><etal/>
</person-group>. <article-title>Lip augmentation with liquid silicone</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>1577</fpage>-<lpage>1585</lpage>; discussion <fpage>1586</fpage>.</citation>
</ref>
<ref id="bibr215-1090820X13484492">
<label>215.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duffy</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Complications of fillers: overview</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>1626</fpage>-<lpage>1633</lpage>.</citation>
</ref>
<ref id="bibr216-1090820X13484492">
<label>216.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dijkema</surname><given-names>SJ</given-names></name>
<name><surname>van der Lei</surname><given-names>B</given-names></name>
<name><surname>Kibbelaar</surname><given-names>RE</given-names></name>
</person-group>. <article-title>New-fill injections may induce late-onset foreign body granulomatous reaction</article-title>. <source>Plast Reconstr Surg</source>. <year>2005</year>;<volume>115</volume>:<fpage>76e</fpage>-<lpage>78e</lpage>.</citation>
</ref>
<ref id="bibr217-1090820X13484492">
<label>217.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dal Sacco</surname><given-names>D</given-names></name>
<name><surname>Cozzani</surname><given-names>E</given-names></name>
<name><surname>Parodi</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Scar sarcoidosis after hyaluronic acid injection</article-title>. <source>Int J Dermatol</source>. <year>2005</year>;<volume>44</volume>:<fpage>411</fpage>-<lpage>412</lpage>.</citation>
</ref>
<ref id="bibr218-1090820X13484492">
<label>218.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carruthers</surname><given-names>A</given-names></name>
<name><surname>Carruthers</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Polymethylmethacrylate microspheres/collagen as a tissue augmenting agent: personal experience over 5 years</article-title>. <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>1561</fpage>-<lpage>1564</lpage>; discussion <fpage>1565</fpage>.</citation>
</ref>
<ref id="bibr219-1090820X13484492">
<label>219.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beljaards</surname><given-names>RC</given-names></name>
<name><surname>de Roos</surname><given-names>KP</given-names></name>
<name><surname>Bruins</surname><given-names>FG</given-names></name>
</person-group>. <article-title>NewFill for skin augmentation: a new filler or failure?</article-title> <source>Dermatol Surg</source>. <year>2005</year>;<volume>31</volume>:<fpage>772</fpage>-<lpage>776</lpage>; discussion <fpage>776</fpage>.</citation>
</ref>
<ref id="bibr220-1090820X13484492">
<label>220.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andre</surname><given-names>P</given-names></name>
<name><surname>Lowe</surname><given-names>NJ</given-names></name>
<name><surname>Parc</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions to dermal fillers: a review of European experiences</article-title>. <source>J Cosmet Laser Ther</source>. <year>2005</year>;<volume>7</volume>:<fpage>171</fpage>-<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr221-1090820X13484492">
<label>221.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimmermann</surname><given-names>US</given-names></name>
<name><surname>Clerici</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>The histological aspects of fillers complications</article-title>. <source>Semin Cutan Med Surg</source>. <year>2004</year>;<volume>23</volume>:<fpage>241</fpage>-<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr222-1090820X13484492">
<label>222.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vochelle</surname><given-names>D</given-names></name>
</person-group>. <article-title>The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience</article-title>. <source>Semin Cutan Med Surg</source>. <year>2004</year>;<volume>23</volume>:<fpage>223</fpage>-<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr223-1090820X13484492">
<label>223.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sidwell</surname><given-names>RU</given-names></name>
<name><surname>Dhillon</surname><given-names>AP</given-names></name>
<name><surname>Butler</surname><given-names>PE</given-names></name><etal/>
</person-group>. <article-title>Localized granulomatous reaction to a semi-permanent hyaluronic acid and acrylic hydrogel cosmetic filler</article-title>. <source>Clin Exp Dermatol</source>. <year>2004</year>;<volume>29</volume>:<fpage>630</fpage>-<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr224-1090820X13484492">
<label>224.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patrick</surname><given-names>T</given-names></name>
</person-group>. <article-title>Polyacrylamide gel in cosmetic procedures: experience with Aquamid</article-title>. <source>Semin Cutan Med Surg</source>. <year>2004</year>;<volume>23</volume>:<fpage>233</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr225-1090820X13484492">
<label>225.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lombardi</surname><given-names>T</given-names></name>
<name><surname>Samson</surname><given-names>J</given-names></name>
<name><surname>Plantier</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Orofacial granulomas after injection of cosmetic fillers: histopathologic and clinical study of 11 cases</article-title>. <source>J Oral Pathol Med</source>. <year>2004</year>;<volume>33</volume>:<fpage>115</fpage>-<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr226-1090820X13484492">
<label>226.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haneke</surname><given-names>E</given-names></name>
</person-group>. <article-title>Polymethyl methacrylate microspheres in collagen</article-title>. <source>Semin Cutan Med Surg</source>. <year>2004</year>;<volume>23</volume>:<fpage>227</fpage>-<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr227-1090820X13484492">
<label>227.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Boulle</surname><given-names>K</given-names></name>
</person-group>. <article-title>Management of complications after implantation of fillers</article-title>. <source>J Cosmet Dermatol</source>. <year>2004</year>;<volume>3</volume>:<fpage>2</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr228-1090820X13484492">
<label>228.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bui</surname><given-names>P</given-names></name>
<name><surname>Pons-Guiraud</surname><given-names>A</given-names></name>
<name><surname>Kuffer</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Slowly absorbable and non absorbable injectable products [in French]</article-title>. <source>Ann Chir Plast Esthet</source>. <year>2004</year>;<volume>49</volume>:<fpage>486</fpage>-<lpage>502</lpage>.</citation>
</ref>
<ref id="bibr229-1090820X13484492">
<label>229.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bedir</surname><given-names>S</given-names></name>
<name><surname>Kilciler</surname><given-names>M</given-names></name>
<name><surname>Ozgok</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Long-term complication due to dextranomer based implant: granuloma causing urinary obstruction</article-title>. <source>J Urol</source>. <year>2004</year>;<volume>172</volume>:<fpage>247</fpage>-<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr230-1090820X13484492">
<label>230.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lemperle</surname><given-names>G</given-names></name>
<name><surname>Morhenn</surname><given-names>V</given-names></name>
<name><surname>Charrier</surname><given-names>U</given-names></name>
</person-group>. <article-title>Human histology and persistence of various injectable filler substances for soft tissue augmentation</article-title>. <source>Aesthetic Plast Surg</source>. <year>2003</year>;<volume>27</volume>:<fpage>354</fpage>-<lpage>366</lpage>; discussion <fpage>367</fpage>.</citation>
</ref>
<ref id="bibr231-1090820X13484492">
<label>231.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Honig</surname><given-names>JF</given-names></name>
<name><surname>Brink</surname><given-names>U</given-names></name>
<name><surname>Korabiowska</surname><given-names>M</given-names></name>
</person-group>. <article-title>Severe granulomatous allergic tissue reaction after hyaluronic acid injection in the treatment of facial lines and its surgical correction</article-title>. <source>J Craniofac Surg</source>. <year>2003</year>;<volume>14</volume>:<fpage>197</fpage>-<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr232-1090820X13484492">
<label>232.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernandez-Acenero</surname><given-names>MJ</given-names></name>
<name><surname>Zamora</surname><given-names>E</given-names></name>
<name><surname>Borbujo</surname><given-names>J</given-names></name>
</person-group>. <article-title>Granulomatous foreign body reaction against hyaluronic acid: report of a case after lip augmentation</article-title>. <source>Dermatol Surg</source>. <year>2003</year>;<volume>29</volume>:<fpage>1225</fpage>-<lpage>1226</lpage>.</citation>
</ref>
<ref id="bibr233-1090820X13484492">
<label>233.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>LH</given-names></name>
<name><surname>Breiting</surname><given-names>VB</given-names></name>
<name><surname>Aasted</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Long-term effects of polyacrylamide hydrogel on human breast tissue</article-title>. <source>Plast Reconstr Surg</source>. <year>2003</year>;<volume>111</volume>:<fpage>1883</fpage>-<lpage>1890</lpage>.</citation>
</ref>
<ref id="bibr234-1090820X13484492">
<label>234.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Friedman</surname><given-names>PM</given-names></name>
<name><surname>Mafong</surname><given-names>EA</given-names></name>
<name><surname>Kauvar</surname><given-names>AN</given-names></name><etal/>
</person-group>. <article-title>Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation</article-title>. <source>Dermatol Surg</source>. <year>2002</year>;<volume>28</volume>: <fpage>491</fpage>-<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr235-1090820X13484492">
<label>235.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Requena</surname><given-names>C</given-names></name>
<name><surname>Izquierdo</surname><given-names>MJ</given-names></name>
<name><surname>Navarro</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Adverse reactions to injectable aesthetic microimplants</article-title>. <source>Am J Dermatopathol</source>. <year>2001</year>;<volume>23</volume>:<fpage>197</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr236-1090820X13484492">
<label>236.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Teuber</surname><given-names>SS</given-names></name>
<name><surname>Reilly</surname><given-names>DA</given-names></name>
<name><surname>Howell</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Severe migratory granulomatous reactions to silicone gel in 3 patients</article-title>. <source>J Rheumatol</source>. <year>1999</year>;<volume>26</volume>:<fpage>699</fpage>-<lpage>704</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>